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Abstract 
 
The research described within this thesis is primarily motivated by two fields of science 
with reversed, yet complementary, approaches to addressing the same essential objective: 
manipulating and understanding the complex program of life.  Whereas synthetic biology 
has to do with the bottom-up construction of living systems from a library of ‘parts’, 
systems biology takes a top-down, reverse-engineering analysis of the same processes 
within functioning cells to elucidate the crucial elements and interactions.  Both 
perspectives have led to important contributions in learning how biological systems 
operate.  Discoveries from these studies can have far-reaching implications, notably in 
medicine, manufacturing, energy, and the environment (1). 
 
One exciting outcome of the research efforts within synthetic biology is the ability to design 
genetic constructs encoding proteins with novel, optimized functions.  Although advances 
have been made in predicting how a protein’s amino acid sequence relates to its higher 
order structural form and behavior, experimental methods for protein engineering remain 
invaluable for evaluating computationally derived designs.  Unfortunately, the design-build-
test cycle for rational protein development is commonly a time, labor and resource 
intensive endeavor.  This is primarily due to limitations in the ability to generate libraries of 
gene variants and bottlenecks in cell-based expression and quantitative screening of 
protein products.   
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This thesis describes the development of a solid-phase gene assembly technique and its 
integration with microfluidic protein analysis to accelerate the prototyping of novel protein 
designs.  The gene assembly method utilizes commodity-scale, chemically manufactured 
DNA, and operates without the need for ligase or restriction enzymes.  As a bench top 
process amenable to scale up, the modularity of the assembly process allows the efficient 
and economical generation of expression-ready gene variants.  We directly coupled this 
gene assembly pipeline to a microfluidic device to enable high-throughput, on-chip, cell-
free protein expression, purification, and characterization.  By circumventing molecular 
cloning and cell-based steps, the lag time between protein design and quantitative 
analysis was dramatically reduced. 
 
As a proof of concept, this protein engineering platform was applied towards the 
construction of over 400 artificial, engineered variants of C2H2 zinc finger (ZF) proteins.  ZF 
protein domains are the most prevalent form of transcription factor (TF) in humans, and 
are found throughout the tree of life.  They provide a convenient structure for refactoring 
due to their relatively small size and composability, and are an ideal model for exploring 
the biophysics of TF-DNA specificity.  The ability to engineer ZF proteins makes them 
useful as programmable, DNA-targeting units for applications in biotechnology and 
synthetic biology.  We demonstrate that although ZFPs can be readily engineered to 
recognize a particular DNA target, engineering the precise binding energy landscape 
remains a challenge.  Additionally, we show that ZF-DNA binding affinity can be tuned 
independently of sequence specificity.  Together, these results demonstrate the versatility 
of the coupled gene assembly and microfluidic analysis platform as a new tool for rational 
protein engineering. 
 
 
 
 
 
 
Keywords: transcription factor; zinc finger protein; microfluidics; MITOMI; high-throughput; 
cell-free protein synthesis; gene assembly; protein engineering; binding affinity; synthetic 
biology; DNA binding domain 
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Résumé 
 
La recherche décrite dans cette thèse se fonde principalement sur deux champs 
scientifiques. Bien qu’opposés, ils sont complémentaires dans leurs approches d’un même 
objectif fondamental : manipuler et comprendre le programme complexe de la vie.  Alors 
que la biologie synthétique a une approche ascendante de la construction de systèmes 
vivants à partir d’un répertoire d’ ‘éléments’, la biologie des systèmes se distingue par son 
approche descendante et ses analyses rétroingénieriques des mêmes procédés au sein 
des cellules vivantes. La biologie des systèmes permet de comprendre quels sont les 
éléments importants et les interactions déterminantes. Les deux approches ont 
grandement contribué à nous faire apprendre le fonctionnement des systèmes 
biologiques. Les découvertes qui en découlent pourraient avoir un impact dans différents 
domaines, tels que ceux de la médecine, de la manufacture, de l’énergie ou encore de 
l’environnement (1).  
  
L’un des résultats intéressants des efforts de recherche dans la biologie synthétique est la 
capacité à concevoir des constructions génétiques codant pour des protéines avec de 
nouvelles fonctions, optimisées. Bien que des progrès aient été réalisés dans la manière 
de prévoir comment les séquences d'acides aminés d'une protéine peuvent avoir un 
impact sur sa forme structurelle d'ordre supérieur et son comportement, les méthodes 
expérimentales pour l'ingénierie des protéines restent indispensables lorsqu’il s’agit 
d’évaluer les prédictions dérivées de modèles computationnels. Malheureusement, le 
cycle conception-construction-test pour le développement de protéines conçues 
rationnellement requiert généralement beaucoup de temps, de travail et de ressources.  
La difficulté à générer des variantes de gènes, ainsi que les obstacles majeurs dans 
l’expression cellulaire et dans le screening quantitatif des protéines en sont les causes 
principales. 
? 8 
Cette thèse décrit le développement d'une technique d'assemblage de gènes en phase 
solide et son intégration dans l'analyse microfluidique des protéines afin d’accélérer le 
prototypage de nouveaux modèles de protéines. Le procédé d'assemblage de gènes 
utilise les produits d’échelle commerciale, de l'ADN fabriqué chimiquement, et fonctionne 
sans l’utilisation d'une ligase ou d'enzymes de restriction. En tant que processus 
d’assemblage visant à être reproduit à grande échelle, la modularité de celui-ci permet la 
génération efficace et économique de variantes génétiques prête à s’exprimer. Nous 
associons directement ce pipeline d'assemblage de gènes à un dispositif microfluidique à 
haut débit pour permettre l’expression, la purification et la caractérisation de la protéine. 
En contournant le clonage moléculaire et les étapes où l’utilisation de cellule est 
nécessaire, le temps de latence entre la conception de protéines et l'analyse quantitative 
est considérablement réduit. 
  
En tant que preuve du concept, cette plate-forme d'ingénierie de protéines a été appliquée 
à la construction de plus de 400 variantes artificielles, toutes conçues à partir des 
protéines de doigt de zinc (DZ) C2H2. Les domaines protéiques des DZ sont la forme la 
plus répandue du facteur de transcription (FT) chez l'homme et se retrouvent tout au long 
de l'arbre de vie. Ils fournissent une structure pratique pour leur remaniement en raison de 
leur petite taille et leur modularité. Ils sont aussi un modèle idéal pour explorer la 
biophysique de la spécificité FT-ADN. La possibilité de concevoir des protéines DZ les 
rend utiles pour des applications en biotechnologie et biologie synthétique puisque leurs 
cibles sont programmables. Nous démontrons que, bien que les DZ peuvent être 
facilement modifiées pour reconnaître une cible particulière d'ADN, l'ingénierie précise de 
l’énergie liaison ADN-DZ reste un défi. En outre, nous montrons que l'affinité de liaison 
d'ADN-DZ peut être régulée indépendamment de la spécificité de la séquence. Ensemble, 
ces résultats démontrent la polyvalence de l'assemblage de gènes, associée à la 
plateforme microfluidique en tant que nouvel outil pour l'ingénierie rationnelle des 
protéines. 
 
Mots clés : facteurs de transcription ; protéines doigts de zinc ; la microfluidique ; MITOMI 
; criblage à haut débit ; synthèse de protéines exempt de cellules ; assemblage des 
gènes ; l’ingénierie des protéines ; affinité de liaison ; la biologie synthétique ; domaine de 
liaison à l’ADN 
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Chapter 1: Introduction 
 
1.1 DNA Oligomers and Gene Synthesis 
 
De novo chemical synthesis of DNA (deoxyribonucleic acid) oligomers has been 
possible since the late 1950s (2), and was a critical tool in the elucidation of the genetic 
code by Gobind Khorana and Marshall Nirenberg in the 1960s (3, 4), roughly a decade 
after James Watson, Francis Crick, Maurice Wilkins and Rosalind Franklin solved the 
structure of DNA in 1953 (5).  Modern oligomer synthesis has its foundation in 
polynucleotide chemistry research from the laboratory of Robert Letsinger during the 
1960s and 70s, which demonstrated oligonucleotide synthesis from a polymer substrate 
and later utilization of phosphorochloridites for faster reactions and improved yields (6, 7).  
Contemporary oligomer synthesis occurs via automated workflows incorporating solid-
phase controlled pore glass (CPG) phosphoramidite chemistry developed in the laboratory 
of Marvin Caruthers(8) in 1981.  The phosphoramidite approach involves a 4-step reaction 
cycle of deprotection, condensation/coupling, capping, and oxidation that extends an 
oligomer chain from a silica (CPG) column substrate (7-10).   
Integrated DNA Technologies (IDT), the world’s largest supplier of custom nucleic 
acids, still produces the majority of its oligomers via CPG columns, which allow 
unidirectional flow of reagents from the core to the reaction surface, where the 3’-affixed 
oligonucleotide grows in the 5’ direction.  Due to imperfect coupling efficiencies dependent 
on both the type of nucleotide being incorporated and its position, oligomer yields 
decrease with length.  In spite of this shortcoming, owing to improvements in reagent 
quality, reaction efficiencies and purification steps, low-cost synthesis of oligomers up to 
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200 nucleotides (nt) with error rates as low as 0.5 per 100 nt has become commonplace 
(11-14).  The development of oligomer microarrays through the use of photolithographic 
techniques coupled with light-directed synthesis reactions in the early 1990s (15), and later 
innovations involving inkjet printing (Agilent Technologies) or electrochemical techniques 
(CustomArray), have significantly reduced oligonucleotide production costs compared to 
column-based synthesis, albeit with considerable reductions in yield and quality (10, 11, 
16-18).  DNA oligomers with lengths approaching 1 kilobase (kb) have been synthesized, 
but these oligomers are extremely low yield and become cost-prohibitive for large library 
sizes.  Considering the technological and scientific achievements since the construction of 
the first synthetic gene in 1970 (19), it is reasonable to expect continued advances in the 
field of oligonucleotide synthesis.   
Gene synthesis, or the fabrication of gene-length DNA constructs, is commonly 
achieved through enzymatic assembly of short oligomer sets into longer chains, which can 
approach lengths of several kilobases (10, 11, 20-23).  One option for enzymatic 
assembly, called ligase chain assembly (LCA), involves the use of thermostable DNA 
ligase to join overlapping oligonucleotide segments spanning the entire length of both 
strands of the gene at elevated temperatures to melt secondary structures (24, 25).  While 
this technique is simple to implement, it is also the most expensive, as it requires 100% of 
the gene of interest to be synthesized since both strands need to be partitioned into 
smaller, gapless units.  Another technique for assembly is polymerase cycling assembly 
(PCA (26) or recursive PCR (27)), which uses polymerase to extend partially overlapping 
(15-25 bp) oligomers, followed by PCR amplification of the full length construct.  Since the 
oligomers are only partially overlapping, this technique is slightly less costly as less 
oligomers are needed for assembly.  Variants of PCA are the TopDown (28, 29) or 
Automatic Kinetics Switch (30) methods, which require special design of oligomers such 
that those in the gene center anneal at high temperatures, while oligomers at the gene 
extremities are designed with decreasing annealing temperatures.  This forces the 
thermodynamics of the assembly reaction such that the core sequence is stringently built 
at high temperatures, and through successive PCR rounds with decreasing annealing 
temperatures, the rest of the gene is extended to its final length.  PCA also requires a final 
round of amplification using primers that anneal at the extremities of the desired product.    
Both ligation- and PCR-based techniques can use conventional column-synthesized 
oligomers or oligomer microarrays for assembly material.  Methods that choose 
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microarrays as their DNA source require additional engineering considerations to address 
the disadvantages of microarray oligomers, such as isolation of sequence-related oligomer 
pools, selection of error-free sequences, and amplification of the source oligomers to 
obtain concentrations conducive to gene assembly (17, 31-36).  Genes synthesized from 
column- or microarray-sourced oligomers will inevitably contain sequence errors, and there 
are a variety of hybridization and enzyme mismatch cleavage techniques available to 
improve sequence fidelity in oligomer source pools as well as the full-length, amplified 
gene constructs (11, 16, 25, 37).  Ligation and PCR-based assembly techniques are 
frequently performed in convenient “one-pot” reactions, which contain all of the oligomer 
segments and terminal amplification primers, but these reactions are not compatible with 
assemblies with high GC content or repetitive stretches.  To circumvent problems arising 
from synthesis of genes containing repetitive stretches, solid-phase iterative capped 
assembly (ICA) (38) and fast ligation-based automatable solid-phase high-throughput 
(FLASH) assembly (39) have been demonstrated as viable ligation-based techniques.   
Following gene assembly, PCR amplified, and error-corrected constructs are 
commonly cloned into plasmids with restriction enzyme digests, transformed into the 
microorganism of interest, and sequenced for verification of error-free constructs.  The 
clever application of fluorescent or colorimetric reporter genes can be used to pre-select 
for errorless assemblies in transformed colonies, since deletions and insertions are the 
predominant error forms in gene synthesis, and only in-frame assemblies will properly 
express the reporter (40).   The time-consuming, expensive and laborious process of 
generating and screening for a single perfect sequence is a major barrier to synthetic 
biology, gene circuit and pathway engineering, genome refactoring, and protein 
engineering, and thus a major obstacle to be overcome.   
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Table 1.1 : Comparison of common gene assembly techniques 
Technique 
Name 
Method of 
assembly  
Advantages Limitations Length scale 
Ligation-
based 
assembly 
Thermostable DNA 
ligase to join 
oligomers, followed 
by PCR amplification 
of full-length 
construct 
Simple to implement, 
secondary structures 
melted at elevated 
ligation temperature, 
one-pot 
Large number of oligos 
must be purchased to 
completely cover both 
strands and have 5’-
phosphorylated ends for 
ligation; cloning and 
sequence verification 
necessary; high GC 
content incompatible 
Limited by 
oligomer 
costs, <5 kb 
(for 
compatibility 
in final PCR 
amplification) 
PCR-based/ 
Polymerase 
cycling 
assembly 
(PCA) 
Partially overlapping 
oligomers are 
annealed and 
extended by 
polymerase (non-
exponential), 
followed by PCR 
amplification of full-
length construct 
Assembly and 
amplification reactions 
in single-step 
procedure; easy to 
multiplex; 15-25 nt 
overlap requires less 
oligomers to span full 
gene; easy to 
introduce targeted 
diversity using 
variants of a single 
oligomer 
Difficulties may occur for 
repetitive sequences or 
secondary structure 
formation; cloning and 
sequence verification 
necessary; higher error 
rates from less 
hybridization-based error 
checking 
<5 kb (for 
compatibility 
in final PCR 
amplification) 
Array-based 
assembly 
Oligomers sourced 
from a microarray 
are amplified and 
used in ligation or 
PCR based 
assembly  
High diversity 
oligomer pools are 
very inexpensive; on 
chip hybridization can 
be used to filter out 
erroneous sequences; 
oligomer subpools can 
be spatially/physically 
segregated to prevent 
cross-hybridization 
Very low concentrations 
of each oligomer in the 
array require PCR 
amplification before 
assembly; higher error 
rates than column-
synthesized; no spatial 
segregation of variants 
(high interference); 
requires high level of 
orthogonality between 
genes to prevent cross-
hybridization of oligomer 
pools 
<5 kb (for 
compatibility 
in final PCR 
amplification) 
 
Larger DNA assemblies with multiple sequence-verified, gene-length parts can be created 
with a variety of methods including circular polymerase extension cloning (41, 42), Golden 
Gate method using type IIs restriction endonucleases and ligation (43, 44), sequence and 
ligation-independent cloning (SLIC) (45), ligase cycling reaction (46), yeast homologous 
recombination (47-50), bacterial recombination (51, 52), seamless ligation cloning extract 
(SLiCE; bacterial and λ prophage Red recombination) (53), Gibson isothermal assembly 
(54), and solid-phase cloning (SPC) (55).   
De novo gene synthesis has many potential applications, and has been used to 
demonstrate the effect of codon bias, promoter design (56-58), examining inducible 
enhancers (59), identifying protein domain interactions (60), constructing genetic circuits 
and engineering recombinant proteins for optimal behavior and expression (33, 61-66), 
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constructing or rewriting synthetic genomes (67, 68), aptamers for therapeutic or 
diagnostic applications (69, 70), and material science projects in which DNA is used to 
construct complex, self-assembling nanostructures, also called DNA origami (71, 72).  The 
emerging applications listed here are only meant to give a glimpse of the diversity of 
scientific questions that can be addressed with synthetic DNA oligomers and gene 
assemblies.  Given the current state of the technology, and the reasonable expectation for 
cost-reducing and quality-enhancing advances in the DNA synthesis industry, it is evident 
that there will be considerable expansion in the domain of gene assembly as future 
applications are explored. 
 
 
1.2 Protein Engineering 
 
Protein engineering is a broad term encompassing all aspects of protein modeling 
and design, modification, expression, and optimization of biochemical activity.  The 
majority of engineered proteins are inspired by structures previously observed in nature.  
Through the use of rational design principles based on computational and experimental 
observations of permutated natural variants, novel functions can be incorporated into the 
protein framework or existing functions can be improved.  Protein engineering is directly 
coupled with gene synthesis, since it is invariably changes in the genetic code that lead to 
successful expression, folding and function of the protein of interest.  The ability to rapidly 
write in DNA, then transcribe, translate and test the associated protein, then process 
multiple iterations of this workflow, would be an invaluable tool to addressing how an 
amino acid sequence underlies protein structure and function. 
There are a variety of approaches to evolving or rationally designing a protein of 
interest for new applications (23, 73).  Experimentally based approaches typically involve 
starting with a naturally occurring form of protein with a given activity, and after generating 
structural diversity through random or focused mutations (74-79), performing a selection 
screen to harvest variants with enhanced activity.  For such experiments, there needs to 
be a direct link between the genotype and phenotype so variants that pass the screen can 
be sequenced and identified.  After investigating the genetic changes that result in the leap 
in function between the wild-type (WT) protein to the new variant, these modifications can 
be used to inform subsequent cycles of design and characterization.  Computational-
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based approaches typically require crystal structures and in depth biochemical analysis of 
a set of variants in order to provide some predictive capability for how other hypothetical 
changes could augment or diminish function (80).  Computational designs inevitably 
require experimental validation, so at best, in silico predictions can be used to restrict the 
multitude of physical forms to be created and evaluated in a functional screen (81, 82).  
Separately, by sampling from natural, well-modeled protein folds and structures, it is 
possible to computationally derive non-natural designs to circumvent the growing but 
limited library of recycled designs found in nature (83). 
 The experimental approach of performing iterations of mutagenesis followed by 
screening is embodied by directed evolution (77, 84-86), which can be a fruitful, but time 
and resource intensive method for generating biological parts with novel functions.  
Mutagenesis is frequently accomplished with error-prone PCR (epPCR), inverse PCR or 
DNA shuffling (78, 87-90).  In phage-assisted continuous evolution (PACE), a mutagenesis 
plasmid is used to allow inducible levels of mutagenesis by proof-reading suppression and 
lesion bypass (91, 92).   
Depending on the breadth of variation and screening technique, targeted, 
systematic, or random modes of mutagenesis can be used to produce libraries with 
increasing levels of genetic variation (62, 77).  Targeted mutagenesis, which modulates a 
limited set of positions with a constrained collection of amino acid residues, requires less 
screening effort to sort through the smaller population of variants, but necessitates prior 
knowledge of which mutations will be relevant and informative for the regions of interest.  
Systematic mutagenesis, such as alanine scanning, methodically changes many individual 
positions to a single residue to track how singular mutations affect function, which can be 
useful for identifying important residues in the absence of structural data, but will omit 
potentially significant interactions that occur between multiple residues.  Random 
mutagenesis produces the most diverse and numerous libraries for screening, enabling 
the recovery of exotic amino acid combinations with improved function, but is highly reliant 
on an effective selection scheme.  Regardless of the method or degree of library 
diversification, the main bottleneck in directed evolution is functional screening of the 
variants.   
Genetic screens used to associate a genotype with an observed phenotype are an 
essential part of the process of directed evolution or even for screening single-gene 
libraries.  These screens can be broadly split into two categories, screens involving 
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spatially segregated variants or screens involving bulk, mixed populations of variants.  
Spatially separated variants can be expressed in single cells of bacteria, yeast or Chinese 
hamster ovary (CHO) cells and examined as colonies or cultures in multi-well culture 
plates, which already limits the throughput of the screening technique (93).  The use of an 
appropriate cell-free protein expression system (discussed further in section 1.5) can offer 
considerable advantages compared to traditional cell-based expression in accelerating the 
process between gene preparation and protein translation (94).  Moving from standard 
culture plates to microfluidic devices reduces the volume of reagents needed for screening 
while improving throughput, but requires photolithography facilities for developing chip 
designs and a microarray printer to individually place the gene variants.  Spatially 
separated screens can be based on optical output (fluorescence, colorimetric, 
luminescence or turbidity) (95) or coupled with nuclear magnetic resonance (NMR), high-
performance liquid chromatography, gas chromatography, or mass spectroscopy to 
measure substrate depletion or product formation.  Other genetic screens can be linked to 
toxic genes or essential genes that require suppression/cleavage or activation/reassembly, 
respectively, via the engineered protein variant in order for the cell to be viable and survive 
the selection (96). 
Genetic screens for mixed variant populations require some method of purifying 
selection to distill out variants with optimal properties.  This can be accomplished using 
fluorescence-activated cell sorting (FACS), which requires a fluorescent-reporter gene 
output or fluorescently labeled antibody to sort variants.  Oil-in-water emulsion droplets, 
agarose droplets or cross-linked polymeric beads can also be used to isolate single 
transformed cells or unique gene constructs within miniature reaction vesicles for 
measuring substrate conversion or fluorescence.  Similarly, microfluidic systems can trap 
single cells or physically isolate arrayed gene variants within unique reaction chambers for 
high-throughput measurements.  Isolated gene libraries that are not transformed into 
microorganisms rely on encapsulated cell-free transcription/translation mixtures for 
expression of the protein of interest (97).  Selections performed for binding affinity can be 
used to screen a mixed population since the full library of variants can be challenged with 
an immobilized target, and only ‘strong’ binders will remain after several rounds of washing 
to remove weak or non-binding variants.  This technique is used in cell surface display or 
biopanning with bacteriophage display in which protein variants are fused to endogenous 
surface proteins (98).  As a solution to the transformation bottleneck observed in surface 
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display techniques, ribosome display can be used to chemically link the growing protein to 
its coding mRNA through in vitro expression using cell extract (99, 100).  In order to 
observe which variants survived the selection and understand what genetic changes 
occurred to arrive at a protein with the desired activity, nearly all screening strategies 
require DNA sequencing to identify optimizing mutations.  By using high-throughput DNA 
sequencing, deep mutational scanning can be used to observe how populations of gene 
variants fluctuate before and after selection (63).  A global comparison of library 
diversification techniques and screening/selection strategies can be found in the review by 
Packer and Liu (2015) (101). 
Prediction algorithms for protein folding and function have improved over the 
decades with the continued growth of experimentally determined three-dimensional protein 
structures (using NMR or X-ray crystallography) and the expanse of sequence information 
produced from massively parallel sequencing technology (102, 103).  Using template or 
homology model building, accurate protein structural models can be derived by comparing 
amino acid sequences to proteins with known structures (104).  Since protein structure and 
function are interrelated, the ability to infer structural form from a protein sequence would 
enable predictions of protein activity and biological interactions directly from the multitude 
of sequenced gene databases.  Additionally, such structural and functional predictions 
would impact studies of protein mutability landscapes and facilitate improved protein 
design guidelines through computational evaluation of mutations (105).  Until predictive 
softwares are capable of robustly generating accurate protein models, experimental 
mutagenesis and functional evaluation of protein variants will remain a necessary part of 
validating engineered protein designs. 
 
 
1.3  Cys2His2 Zinc Finger Transcription Factors 
 
Underlying the complex network of interactions governing cellular growth, 
development, internal signaling, and responses to external stimuli, is a broad class of 
proteins called transcription factors (TFs) (106).  TFs bind to specific regulatory DNA 
sequences (TF binding sites – TFBSs (107, 108)) and modulate the process and rate of 
transcription of genetic information from DNA to messenger RNA (mRNA).  TFs can 
induce these changes in transcription through several mechanisms, by binding a given 
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DNA sequence alone or in concert with other proteins, and recruiting (gene activation) or 
blocking (gene repression) transcription machinery from assembling at the gene location.  
In combination with other proteins, TFs can also direct chromatin remodeling by regulating 
histone proteins (via post-translational modification by acetylation or deactylation (109)), 
thereby altering the degree of condensation of the DNA coding for a gene, changing the 
accessibility of the gene to transcription machinery (110).  TF proteins are structurally 
modular with a DNA-binding domain (DBD) (111) that attaches to a specific sequence of 
DNA and closely-related variations.  They also typically include a signal-sensing domain 
(SSD) that binds ligands and a trans-activating domain (TAD) that provides a docking site 
for other proteins.  Both the SSD and TAD add levels of complexity to the transcriptional 
regulation of a particular gene.  There also exists DNA-binding proteins that are also 
capable of binding to RNA, and in the context of TFs, this may facilitate still other modes of 
transcriptional regulation through competitive binding of DNA and RNA targets, altering 
mRNA stability and translation efficiency, and recruiting other proteins to a DNA target site. 
There are many types of DBDs in TFs, the most prominent being helix-loop-helix 
(HLH), leucine zippers, homeodomains, and zinc finger (ZF) proteins (112-115).  By far, 
the ZF protein family is the most prevalent form of DBD and can be found across the tree 
of life (76, 116-118).  The Cys2His2 ZFs (C2H2-ZF) comprise the largest class of DBDs in 
metazoans, and exist as solitary domains, but are more commonly seen as an array of 
multiple C2H2-ZF domains in tandem (76, 118-120).  The C2H2-ZF domains are relatively 
small, 30 amino acid (aa) units, organized around a ββα configuration (Figure 1.3.1).  Each 
C2H2-ZF tetrahedrally coordinates around a single zinc ion through interactions between 
two cysteine (Cys) residues within the two-stranded antiparallel β-sheet and two histidine 
(His) residues in the α-helix.  DNA sequence specificity can be tuned primarily by changing 
residues -1, 2, 3, and 6 in the α- or ‘recognition’ helix (76, 121, 122).   
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Figure 1.3.1 : Cartoon model of canonical Cys2His2 ZF TF binding to DNA with residues -1, 2, 3 and 6 of the 
recognition helix primarily encoding DNA specificity.  Residue 2 makes a cross-strand contact, which creates 
‘context dependent’ effects.  Zinc ions are colored in light blue. 
 
For a single ZF module, these residues are directly involved in targeting a 3-4 base-
pair (bp) DNA address, while tandem ZF arrays bind to longer DNA sequences essentially 
made up of the concatenation of the individual target sites of each module in the array.  
Due to a cross-strand base interaction from residue 2 in the recognition helix with the first 
nucleotide in the complementary strand of the 3’-adjacent target triplet, some DNA targets 
of ZF arrays are not simply concatenations of the different DNA target sites.  This target 
site overlap is a characteristic of tandem ZF arrays, creating an effect called ‘context 
dependence’ (119), is the primary reason for the lack of a ‘recognition code’ or a set of 
general guidelines for designing an optimal ZF array for any desired target site (120, 123).  
The context dependent interactions between adjacent C2H2-ZFs complicates predictive 
modeling of their DNA-binding specificities, and poses a considerable challenge to 
engineering C2H2-ZFs with precise targeting capabilities. 
  C2H2-ZF domains are unique among TFs in that by altering the DNA specificity 
residues in the α-helix, they could hypothetically be used to target every possible DNA 
triplet of interest. Their versatility as a modular DNA targeting unit is evident from their 
abundance and diversity in eukaryotes, but also in the limited number of conserved 
residues within the C2H2-ZF structure, which relies on stabilization through zinc ion 
coordination and a conserved hydrophobic core.  The prevalence of ZF TFs, particularly 
tandem arrays, in eukaryotes has been traced to a gene family that expanded through 
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repeated duplications concurrent with functional binding divergence (123).  Arrays of C2H2-
ZF in humans can range from 4 tandem units to more than 30, with an average of 8.5, 
which in theory would bind a 25 bp target (123-125).  A random target of 16 bp (5 C2H2-ZF 
tandem units) is sufficient to encode a unique site within the human genome (∼3×109 bp), 
so longer target sites seem superfluous even with consideration of binding site degeneracy 
within C2H2-ZF modules.  It is believed that longer tandem arrays operate not to bind a 
single, specific target but to bind multiple targets with varying sets of C2H2-ZF units in 
different genetic contexts (126).  This multifarious behavior can also be inferred from 
experiments involving artificially created C2H2-ZF arrays, wherein binding affinity does not 
significantly improve beyond 4 tandem units.  The C2H2-ZF domain is not limited to binding 
DNA targets, and natural variants have been observed binding hybrid DNA/RNA strands, 
proteins, and both single-stranded and double-stranded RNA (124, 127, 128).  Due to the 
small size, versatility and modularity of C2H2-ZFs, their structure has also been used as a 
scaffold to create combinatorial peptide libraries for the evolution of novel binding 
properties (129, 130). 
In spite of the engineering challenges in creating artificial C2H2-ZF arrays, the utility 
of a modular DBD with tailored binding specificities was too alluring to be overlooked.  The 
creation of molecules capable of binding DNA to specifically regulate genes and thereby 
influence cellular development and physiology remains a major ambition of personalized 
medicine and synthetic biology.  Shortly after the crystal structure of a peptide containing 
the natural triple C2H2-ZF array from Zif268 (a human and murine TF protein, also called 
‘early growth response’ EGR1) bound to DNA was solved (131, 132), there was a surge of 
interest in engineered ZF applications.  Initial synthetic ZF research efforts dealt with 
searching for a DNA-binding recognition code (121,133-136), using phage display (137-
142) or other techniques as a screening mechanism to find variants that bound each 
possible DNA target triplet.  Engineered C2H2-ZF arrays are typically based on the Zif268 
peptide or Sp1 (taken from the consensus of human TF Sp1, another triple C2H2-ZF) (143, 
144) framework.  Either of these naturally occurring proteins is taken as a template 
structure or ‘framework’ and a library of recognition helices from available databases or 
binding models (75, 76, 145-148) with different DNA target specificities are inserted.  
Variants with differing linker sequences and lengths between individual C2H2-ZF modules 
have also been tested (149).  The refactored protein is then tested against a set of DNA 
targets to evaluate the actual binding energy landscape of the new protein construct.  
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Many techniques for constructing ZF libraries from synthetic oligomers or plasmid libraries 
have been proposed (144, 147, 148, 150-152) and implemented with different selection 
schemes.   
Engineered ZF domains have been constructed as artificial transcriptional activators 
or repressors (153-157), as cell-membrane penetrating carrier domains for transporting 
proteins (158, 159), and as dsDNA sensors in diagnostic applications (160-162).  Their full 
potential was realized by simply using them as DNA-targeting moieties for a plethora of 
protein fusions with different effector/enzymatic domains such as integrases, 
recombinases, invertases, transposases, chromatin regulators (157), and most commonly 
nucleases (153, 163-173).  Considerable effort was applied in engineering ZF nucleases 
(ZFNs) which are typically designed as a dimerizing pair of FokI nuclease subunits 
tethered to two different 3-4 C2H2-ZF tandem units that bind on opposite strands of the 
target cut-site.  ZFNs are in competition with TAL (transcription activator-like) effector 
nucleases (TALENs), which have a solved recognition code, but consist of considerably 
larger DBDs, and also easily implemented CRISPR-Cas (clustered regulatory interspaced 
short palindromic repeat) RNA guided DNA endonucleases (174).   
 
 
1.4 Methods for measuring TF-DNA interactions 
 
There exists a diverse collection of experimental methods for both qualitatively and 
quantitatively detecting and measuring the DNA binding specificity of TFs in vitro and in 
vivo.  These methods are often used in conjunction with computational approaches to 
enable binding-site or motif-discovery predictions and infer the network architecture of 
genetic regulatory systems (175-178).  Since TFs must be able to locate, distinguish and 
bind their specific regulatory elements within a genome containing an excess of competing 
binding sites, the binding specificity of TFs is crucial for understanding how regulatory 
networks function (108, 176).  By mapping which DNA elements are important in 
transcriptional regulation, it is possible to understand how TFBSs influence mRNA 
translation as well as generate the phenotypes created by the proteins they encode.  
Additionally, by resolving the regulatory networks within cells, it is possible to determine 
the source of different disease states caused by genetic variations that disrupt normal 
gene expression. Whereas in vitro experimental methods are primarily useful for 
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identification of TF consensus binding sites, determination of binding energy landscapes or 
evaluating biophysical parameters, in vivo methods provide genome-wide information 
within the context of different environmental conditions and biological settings (ie cell type 
or developmental stage).   
 
 
1.4.1 In vitro Methods 
 
EMSA and Nuclease Footprinting (Classical techniques) 
One of the classical methods for in vitro characterization of protein-DNA interactions 
is electrophoretic mobility shift assays (EMSA) (179) and related methods (180).  This 
technique is relatively inexpensive, but low-throughput and time/labor intensive, and can 
provide a quantitative measure of TF-DNA binding.  In these assays, a TF or protein 
mixture is incubated with a potential DNA target.  If protein binding occurs, the migration of 
the protein-DNA complex through an agarose gel within an electric field is impeded 
compared to unbound DNA, causing it to run more slowly through the gel resulting in a 
spatial shift of the band.  This technique is usually reserved for qualitative analysis of TF 
binding activity, and is commonly bypassed in favor of other more comprehensive, data-
rich, yet elaborate, characterization techniques.   
Nuclease footprinting analysis is another classical technique developed in 1978 for 
determining the target sites of DNA-binding proteins (181-183).  This technique is based 
on the fact that TFs bound to DNA will protect the phosphate backbone from cleavage 
during incubation with DNase-I.  A DNA target sequence, between 50-200 bp long, with a 
fluorescent or radioactive label at one end is incubated with the TF, then digested.  The 
same DNA is digested in the absence of the TF, which will produce random cuts.  The 
labeled DNA products from both reactions is run on a gel to visualize the resulting DNA 
fragment pattern (footprint), and by comparing the DNA products, binding site and kinetic 
binding constants can be determined.    
 
SELEX 
SELEX (systematic evolution of ligands by exponential enrichment) (176, 184, 185) 
involves exposing purified TF to a large oligonucleotide library containing randomly 
generated or genomic sequences of uniform length but flanked by universal primer binding 
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sites.  Sequences bound by the TFs are amplified by PCR whereas unbound sequences 
are washed away or separated from TF-DNA complexes via gel filtration.  The amplified 
DNA is used for additional rounds of selection and amplification and in the end, the 
remaining bound targets are cloned and sequenced or used directly for massive, parallel 
sequencing (SELEX-seq) to identify the highest affinity target sequences (186, 187).  A 
single round of oligomer binding, capture, amplification paired with high-throughput 
sequencing (Bind-n-Seq) was found to be sufficient to correctly identify consensus binding 
sites and give approximate target affinities based on the frequency of sequence reads 
(188).   
SELEX was one of the first techniques capable of de novo TFBS consensus 
determination without any prior knowledge of TF binding site preferences. High-throughput 
(HT-SELEX) can be accomplished by using DNA barcodes included within the sequence 
of the oligomer library to uniquely identify individual SELEX samples (different TFs) after 
pooling bound DNA elutes and performing massively parallel sequencing (187).  Since 
SELEX requires purified TF for binding, non-natural concentrations of TF relative to the 
oligomer library may result in the detection of binding artifacts, and the TF of interest may 
be missing relevant post-translational modifications (phosphorylation, hydroxylation, 
acetylation) (189, 190), binding cofactors, or ligands that alter the binding behavior due to 
expression in foreign systems.  Additionally, because SELEX requires a washing or gel 
filtration step to separate the TF-DNA complexes from unbound sequences, it may fail to 
detect weak-affinity interactions, reducing the sensitivity of binding detection.  Finally, the 
need to amplify TF-captured DNA with universal primers may introduce amplification bias 
or lead to the creation of chimeric sequences which result in inaccurate reporting of the 
abundance of sequences, skewing the approximation of relative binding affinities for 
different targets (191, 192). 
 
PBM 
Protein binding microarrays (PBMs) (141, 185, 193-195) can also be used for high-
throughput, de novo identification of TF consensus sequences.  This method involves 
incubating an epitope-tagged or fluorophore-labeled TF, either purified or within cell 
nuclear extract, with a dsDNA microarray.  The dsDNA array starts as ssDNA and the 
complementary strand is produced via primer extension prior to introducing the TF.  After 
washing to remove nonspecifically bound TF, locations of TF binding are detected with 
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either direct fluorescent signal from the TF or using a fluorescently labeled antibody 
targeting the presented epitope tag. The specificity of the TF can be determined by 
comparing the relative fluorescence levels across target spots.  Although PBMs offer a 
rapid method for identifying TFBSs, they may not necessarily provide accurate predictions 
of endogenous TF binding due to missing cofactors or chromatin structure, and the 
microarrays themselves usually have DNA length and array density limitations that may 
require additional experiments to map a large sequence space.  PBMs also require 
multiple washing and blocking steps to remove nonspecific binding events from being 
detected, but this simultaneously reduces the sensitivity of the screen since weak-affinity 
interactions will be disrupted and overlooked.   
By utilizing phage display and DNA microarrays, a procedure similar to SELEX can 
be used to repeatedly select and amplify in liquid culture phage bound to a target DNA, 
followed by sequencing of the phage inserts to determine the identity of the protein (138, 
196).  Another technique similar to PBMs is CSI (cognate site identifier) (122) which uses 
a ssDNA microarray where each strand folds back on itself to form a dsDNA hairpin target.  
To examine TF binding, rather than requiring fluorescently tagged protein or labeled 
antibody for detection, a DNA intercalating dye is used to compete with TFs for DNA 
binding (FID, fluorescent intercalator displacement) (197). 
 A technique related to promoter disruption analysis and PBMs, termed synthetic 
saturation mutagenesis, utilized a DNA microarray to systematically create a library of 
barcoded, single- or double-nucleotide mutations and point deletions within promoter 
regions for known phage RNA polymerases (198).  Using in vitro transcription extract and 
reverse-transcriptase PCR with short read sequencing to map important DNA elements by 
counting the distribution of barcodes retrieved, the technique was able to determine 
residues within the ‘footprint’ of polymerase binding, but also identify some position- and 
nucleotide specific variants that enhanced transcription compared to the native promoter.  
The technique was also applied to mammalian promoters using HeLa nuclear extract.  
Although this approach was successful at identifying important promoter elements, it 
required prior knowledge of the binding sequence to generate a library within the length-
restrictions of synthetic DNA microarrays.  
 Finally, a variation of PBMs integrated with second generation, high-throughput 
sequencing, called HiTS-FLIP (‘high-throughput sequencing’-‘fluorescent ligand interaction 
profiling’) (107, 199), was developed and validated by studying DNA binding interactions of 
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the yeast protein Gcn4.  The process requires the use of a sequencing instrument, wherein 
millions of different DNA targets, localized in distinct clusters of identical sequence, are 
sequenced by incorporation of fluorescently labeled nucleotides.  Once the sequence 
identity of each cluster is determined, the synthesized strand is melted away and the 
substrate-bound target strand is used in a Klenow reaction to generate dsDNA clusters.  
The purified, fluorescently labeled protein of interest is then washed across the flow cell of 
the sequencing instrument at increasing concentrations, and binding events are captured 
by imaging.  By superimposing the fluorescent images generated during sequencing with 
those from protein-binding steps, the DNA clusters that are bound by the protein can be 
identified.  Although this technique offers higher throughput and sensitivity than PBMs and 
can screen longer target sequence libraries, it requires expensive sequencing instruments 
and can only study one protein at a time.       
 
SPR 
SPR (surface plasmon resonance) (179, 200, 201)  functions on the principle that 
light is reflected from a thin layer of gold at different angles depending on the composition 
of molecules adsorbed to the opposite (non-incident) surface of the gold layer.  The light 
that hits the gold creates a plasmon wave in the plane of the gold layer, and the 
oscillations of the wave are highly sensitive to irregularities in the gold surface such as 
adsorbed proteins.  The angle shift of reflected light compared to a reference (before 
protein is introduced) can be used to measure the amount of adsorbed material on the 
surface.  BIAcore presented the first commercial SPR system for detecting biomolecular 
interactions and measuring binding affinity, and hence the company name is commonly 
associated with the technique.  The method requires a protein or DNA target to be 
immobilized on the sensor chip surface, then the binding partner is introduced at different 
concentrations and interactions with the surface-bound analyte are recorded via 
fluctuations in the angle of reflection.  The technology can be used to monitor both 
association and dissociation kinetics of any biomolecular binding-pair by washing the 
surface until equilibrium is reestablished.  For studying TF-DNA interactions, a high-
throughput variation of SPR can be realized by arraying multiple DNA sequences to the 
sensor surface, enabling parallel detection of binding events using a single TF.  SPR 
technology provides a label-free alternative to detecting and measuring TF-DNA 
interactions with low sample amounts, and although measurements can be made rapidly 
? 29 
with high sensitivity, the technique has several disadvantages.  Firstly, without a method 
for signal amplification, SPR requires at least 0.1% of substrate-linked molecules to attach 
to their binding partner in order to detect the interaction (202), which limits its efficacy to 
detect low affinity interactions.  Secondly, the surface must be functionalized and 
sufficiently blocked to prevent non-specific adsorption, which can lead to the production of 
false signals.  Finally, as with other in vitro techniques discussed previously, protein 
behavior in vitro may not accurately represent in vivo activity. 
 
MITOMI 
MITOMI (mechanically induced trapping of molecular interactions) is an in vitro 
technique combining aspects of PBMs with microfluidics to achieve high-throughput 
detection of low-affinity and transient TF-DNA binding events (203, 204).  The realization 
of microfluidic large scale integration (MLSI) is the primary technological advance enabling 
the MITOMI principle (205, 206).  The MITOMI microfluidic device is composed of 
hundreds to thousands of physically separated unit cells (Figure 1.4.1 and 1.4.2), which 
are sealed via pressure-driven actuation of silicone elastomer (polydimethylsiloxane, 
PDMS) valves. 
 
Figure 1.4.1: A schematic of the 1024 chamber MITOMI device used for all of the experiments described in 
this publication.  On the far left are several ports where PBS-filled control lines are inserted to actuate 
microfluidic valves on the device with compressed air.  The last 4 lines (in red) control the button valve, 
sandwich valve, neck valve and chip exit valve, from top-to-bottom, respectively. The flow lines are where 
experimental buffers/reagents are inserted to flow across the chip.  The operation of the device is detailed in 
the methods section.  
 
 
PDMS begins as two components, a liquid polymer base and a curing agent, and 
after mixing and baking, crosslinks to form an elastomeric, transparent, gas- and water-
? ????????????? ????????????
?????????
??????????
??????????????
????????????
??????????
???????????????
???????????????
???????????????
???????????????
???????????????
???????????????
???????????????
?????????? ?????????????????????????????
??????????????????????????????????????????????????
? 30 
permeable, biologically-compatible material (207).  By casting the uncured mixture over a 
micropatterned surface, a microfluidic device, composed of micron-sized features, can be 
produced.  The device is composed of two separate overlaid layers (termed the control 
and flow layers; Figure 1.4.3) created using standard multilayer soft photolithography 
techniques. 
                        
Figure 1.4.2: A cartoon of a three MITOMI unit cells with labels for the button, sandwich and neck valves.   
 
 
 
 
 
 
 
Figure 1.4.3: A cartoon image of the control layer (gray) positioned overtop the flow layer (blue).  By 
pressurizing water or another fluid in the channels above the flow layer, the thin flow layer membrane can be 
deflected and pressed against the surface substrate. 
 
The control layer containing channels for actuating the flexible valves is placed on 
top of the flow layer, which contains channels and chambers for flowing experimental 
reagents and conducting biological assays (Figure 1.4.3).  Each unit cell (Figure 1.4.2) is 
composed of two compartments, the reaction chamber and the DNA chamber, and is 
controlled by three valves termed the sandwich, neck and button valves.  The sandwich 
valves function to seal each unit cell from neighboring chambers to prevent mixing and 
contamination between reaction chambers. The neck valves function to protect the DNA 
chamber from rehydration until after the experimental surface is appropriately blocked and 
patterned for the assay of interest.  A single button valve per unit cell (centrally placed in 
the reaction chamber) is used for surface derivatization and molecular interaction trapping 
and protection during washing steps.  The device is aligned over a DNA microarray printed 
onto an epoxy-functionalized glass microscope slide such that each DNA chamber 
Control valve activated
 (pressure on)
Control valve deactivated 
(pressure off)
Control layer
Flow
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encloses a single spot of deposited target DNA.  Through successive rounds of flowing 
biotinylated-BSA (bovine serum albumin), neutravidin (a deglycosylated form of avidin), 
then activation of the button valve to protect a circular area within the reaction chamber 
and flowing biotinylated-BSA to block the remaining area in the reaction chamber, an 
island of neutravidin is produced.  The surface can then be functionalized with a 
biotinylated antibody for precipitation of tagged protein.  In the case of TFBS analysis with 
MITOMI, each DNA chamber contains a different fluorophore-labeled DNA target 
sequence or concentration.  Protein expression can be performed off-chip then the 
assembled protein can be flowed across the device and captured by the surface-bound 
antibody, or the protein DNA template can be arrayed with the DNA targets and in situ 
expression can be performed by incubating the templates with cell-free extract (in vitro 
transcription/translation mixtures).  In this way, the MITOMI device functions to 
compartmentalize a TF array with different DNA targets to evaluate binding interactions, in 
a manner similar to nucleic acid programmable protein arrays.  Protein-DNA interactions 
are captured by activating the button membrane and washing away unbound material in 
each reaction chamber.  An experimental variation of MITOMI that does not require 
antibodies involves surface-bound biotinylated and fluorescently-labeled target DNA and 
trapping proteins interactions after incubation.  The protein is expressed with fluorescently-
labeled amino acids (ie using the commercially available FluoroTect™ BODIPY®- FL 
labeled tRNA-lysine from Promega) or as a fusion protein with a fluorescent domain so 
that trapped protein and bound target DNA amounts can be quantified with fluorescent 
calibration curves.  The MITOMI principle has been used to analyze TF binding 
preferences (204, 208-211), protein-protein interactions (212-214), immunodiagnostics 
(215), and protein-RNA interactions (216).  
 
 
1.4.2 In vivo Methods 
 
In vivo methods are a necessary complement to in vitro TFBS interrogation 
techniques, largely due to the need to evaluate how well in vitro results translate to living 
systems, but in general it appears TF binding models based on analysis of in vivo or in 
vitro data are equally accurate (217).  As with in vitro techniques, there exists a selection 
of in vivo techniques to evaluate TF binding within a biologically relevant system.  One in 
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vivo time and labor intensive approach to TFBS discovery is gene disruption/promoter 
deletion analysis (218, 219) paired with a genetic reporter to give a visual read-out of the 
transcriptional effect of removing or altering a given DNA regulatory element.  Molecular 
barcoding can be used for sequencing or microarray hybridization to identify which 
sequences are valuable for expression.  Although screening of the expression level of the 
reporter gene can be used to provide a quantitative output, subtle differences in 
transcription are difficult to detect.   
A technique related to gene disruption utilizes a set of synthetic promoter libraries 
built with random combinations of TFBS to form ‘building blocks’, examined their effect on 
fluorescent protein expression in yeast, and used these datasets to train a thermodynamic 
model for prediction of gene expression from promoter sequence (220).  Although the 
technique was useful to successfully predict gene expression controlled by a single TF for 
genes with related promoters, the experimental throughput was limited to examination of a 
single TF, with considerable resource and labor requirements.  Other in vivo techniques for 
TFBS characterization, described below, can be broadly categorized as population-level or 
single-cell techniques (221).  
 
 
ChIP 
ChIP (chromatin immunoprecipitation) is a technique for the discovery of TFBSs in 
vivo which has its basis in a method developed in 1978 to study histone-DNA interactions 
(222) and has undergone significant modifications and improvements since (223, 224).  
This population-level technique involves the chemical fixation of all protein-DNA 
interactions within a large pool of cells (∼107) (225), which covalently crosslinks the DNA-
binding proteins to their targets.  After cell lysis, DNA extraction and shearing the DNA via 
sonication, protein-bound DNA fragments are selectively purified with an antibody specific 
to the TF of interest or with an antibody against an epitope-tag that is presented by a 
modified TF.  The crosslinking is reversed and the DNA fragments were analyzed, in the 
classical version of the technique, by PCR, hybridization with labeled probes, or molecular 
cloning and sequencing.  More recent developments for analyzing the captured DNA 
involve the use of DNA microarrays in a technique called ChIP-on-chip (or ChIP-chip) 
(194), or ChIP-sequencing (ChIP-Seq) which uses high-throughput sequencing (226).  
ChIP-chip begins by first amplifying the captured DNA fragments, labeling them, then 
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incubating the fragments with a ssDNA microarray for hybridization.  After a series of 
washes, the hybridized array is scanned and image processing software is used to 
evaluate the signal locations and intensities to determine sequence identities and relative 
enrichment levels.  ChIP-Seq directly sequences all of the purified DNA fragments, offering 
higher resolution, direct quantification of enriched sequences, better genome coverage 
and reduced levels of artifacts compared to ChIP-chip (190).  A refinement of ChIP-Seq, 
called ChIP-exo, involves the use of DNA nucleases (lambda exonuclease or DNase-I) to 
improve the resolution of a given TF binding site (229, 230).  For ChIP-exo, following the 
DNA fragmentation step, the DNA outside of the TF-protected region is digested and the 
length of the DNA fragment that is sequenced is reduced from ∼100-500 bp to 25-50 bp, 
improving the precision of TFBS discovery (224).   
Though ChIP and related variants can be used to provide population-averaged, 
genome-wide association studies for single TFs, these results are highly dependent on TF 
abundance, the efficiency of crosslinking, and the availability of an antibody for purification.  
ChIP techniques are also restricted to capturing direct, high affinity TF-DNA interactions 
that do no require cofactors for binding in accessible genomic regions (free of 
nucleosomes), which may not include the complete DNA sequence space and can vary in 
different cellular settings.  The majority of these limitations can be overcome using in vitro 
TFBS mapping methods. 
 
 
DamID 
A second in vivo technique, called DamID (194, 231, 232), is based on the 
methylation of nearby DNA when bound by a TF fused to the DNA adenine 
methyltransferase (Dam) protein.  Dam methylates the adenine within the sequence 
‘GATC’ which occurs on the order of several hundred times depending on the length of the 
genome being examined.  Restriction enzymes specific to methylated DNA (DpnI) cleave 
the methylated regions, which are amplified, labeled and hybridized to a DNA microarray 
or the methylated DNA can captured with an antibody after shearing and sequenced.  
Although this technique is not limited by requiring an antibody specific to the TF of interest, 
the binding site mapping resolution of this technique is relatively coarse due to the 
frequency of GATC sites.  Another detracting feature of this technique is that the gene 
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coding for the TF-Dam fusion is typically overexpressed from a plasmid, which may lead to 
binding-site artifacts as a result of non-natural cellular TF concentrations. 
 
 
Y1H/B1H 
The yeast or bacterial one-hybrid (Y1H or B1H) technique is a powerful in vivo 
genetic tool for identifying TF variants that bind a DNA element that was based on the Y2H 
(yeast 2-hybrid) technique (227, 228, 233, 234).  Both one-hybrid techniques function on 
the basis that some modular TFs consist of both a DBD and a transcription activation 
domain (TAD).  Any TF that can be cloned and expressed in S. cerevisiae or E. coli can be 
examined using this technique.  Generally, two plasmids are required for transformation: 
one containing the gene encoding the TF of interest fused to a subunit of RNA polymerase 
(frequently the omega subunit for B1H) or an activation domain from a yeast TF (such as 
the TAD of GAL4 for Y1H), and a second plasmid containing either a fixed or randomized 
binding site located upstream of a weak promoter controlling expression of 
essential/selectable reporter genes (235-238).  The DNA binding site is commonly referred 
to as the ‘bait’, while the TF-TAD fusion is called the ‘prey’.  The plasmids are usually 
transformed into mutated cell lines that are auxotrophic for tryptophan, leucine, histidine, or 
uracil (lacking TRP1, LEU2, HIS3 or URA3, respectively), meaning they cannot grow on 
media lacking these compounds are require recovery of the gene to survive.  In the event 
that the TF-TAD fusion is capable of binding the bait site with sufficient affinity to activate 
the promoter and trigger essential gene expression, the auxotrophy is rescued, those cell 
survive to form colonies on minimal media, and the prey-bait combinations can be 
sequenced to determine the identity of each TF variant and its binding sequence.  As an 
alternative to auxotrophic rescue selection, the bacterial gene LacZ can be used in both 
B1H and Y1H with media containing X-gal as a selectable, colorimetric (blue colony) 
reporter in combination with one of the essential genes.  This technique can be used in 
two different modes, either by taking a TF of interest and screening a binding site library 
for baits that it captures, or by testing variants of TF and selecting for those that bind a 
specific target sequence of interest.  In several C2H2-ZF variant screening studies 
employing the B1H method (75, 76, 152, 233, 239), the bait plasmid contains both HIS3 
and URA3 which enables positive and negative selection strategies.  By introducing 3-
amino-triazole (3-AT) a competitive inhibitor of HIS3, only strongly-activating interactions 
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(associated with higher expression levels of HIS3) are captured in colonies which survive 
the inhibitory selection.  Separately, by introducing 5-fluoro-orotic acid (5-FOA), which 
becomes toxic when metabolized in the uracil biosynthesis pathway, active promoters that 
function regardless of the bait sequence (TF-TADs that function by binding outside the bait 
site) can be eliminated from the screen.  The use of URA3 as a selectable marker comes 
with the caveat that it is characterized by having a high background since cells with 
mutations in URA3 may survive on media with 5-FOA.  In general, the use of double 
reporters for B1H and Y1H assays reduces the frequency of false positives and is easily 
implemented in most selection schemes.     
Other technical improvements for B1H and Y1H are outlined by Reece-Hoyes and 
Walhout (235).  Since both B1H and Y1H are reliant on DNA sequencing to retrieve the 
DNA bait sequence or the TF variant sequence, this method can be limited to the number 
of colonies that can be picked, unless massively parallel sequencing and DNA barcoding 
is used to multiplex many different TF variants for unique target sites from different 
selections.  The primary limitation in B1H/Y1H is the creation of a diverse enough library to 
properly assess a broad sequence space of potential TF designs, but also the 
transformation efficiency of the strains used.  Additionally, since these assays are carried 
out in vivo, TF variants that bind strongly to the endogenous DNA of the strains used may 
impart a fitness cost to the organism by disrupting normal gene expression, while weak-
affinity variants will not survive the selection steps, and thereby misrepresent the detection 
of functional variants (190).   
 
 
1.5 Cell-free Protein Expression 
 
Crude cell-free extracts have been an important tool utilized by biologists for over a 
century, since Eduard Buchner first metabolized sugar to ethanol and carbon dioxide using 
yeast ‘press juice’ in 1897 (240), to deciphering of the genetic code by Nirenberg and 
Matthei during the 1960s (3, 241), to the multitude of recent scientific and industrial 
applications (242).  Cell-free transcription and translation (TX-TL) systems are 
indispensible tools for accelerating synthetic biology and protein engineering research 
applications (93, 242-244).  Expressing genetic constructs within an experimentally 
isolated, cell-free system enables the analysis of novel proteins and gene networks 
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detached from the biological noise of essential processes in living organisms.  By 
circumventing labor- and reagent-intensive traditional molecular cloning, transformation 
and cell culture steps, cell-free extracts offer a versatile means of rapidly and economically 
obtaining practical titers of protein from recombinant DNA templates, freed from the myriad 
constraints of maintaining viable cells.  Cell-free extracts have been demonstrated to 
drastically reduce the time necessary to test synthetic gene parts and networks (245), and 
recent applications have even proven the viability of using cell-free systems for rapidly 
prototyping engineered circuits in paper-based platforms (246).    
Cell-free protein expression systems can potentially be made from any organism.  A 
wide variety of cell types can be used depending on the complexity of the protein to be 
synthesized, ranging from prokaryotic and protozoan, to plant, insect and mammalian cells 
(247).  In addition to conventional cell types, cell extracts can also be produced from 
genetically modified cell strains with special mutations or synthetic genes to enhance 
protein production, folding, stability, or modification.  The choice of which cell-free system 
to use is dependent on cost, the quantity of protein desired, and whether specific protein 
folding chaperones, cofactors, or post-translational modifications are needed.  The most 
commonly used, and commercially available, cell-free extracts are made from E. coli, 
wheat germ, and rabbit reticulocyte (243, 248).  A crude cell extract, while time and labor-
intensive to prepare, is generally sufficient for most protein synthesis applications.  Crude 
extracts are produced by harvesting a large volume of cultured cells via lysis (bead 
beating, sonication or high-pressure), centrifugation to remove cell wall fragments and 
genomic DNA, a ‘run-off’ reaction to release and degrade residual mRNA from captured 
ribosomes, and dialysis to transfer the TX-TL constituents into a suitable storage buffer 
(244, 249). These extracts are also referred to as “S30” fractions since the soluble cell 
components and ribosomes are found in the supernatant after centrifugation at 3×104g.  
The final extract contains all of the essential cellular components for protein synthesis: 
ribosomes, tRNAs, tRNA synthetases, amino acids, translation factors, nucleotides, 
nucleotide recycling enzymes, metabolic enzymes, energy substrates, cofactors, and salts 
(243, 248).  
 Since most TX-TL systems are operated as batch or batch-fed reactions, which 
exhibit reduced yields over time due to increasing levels of inhibitory byproducts and 
declining substrate and energy sources.  Significant changes in the preparation and use of 
cell-free extracts have been made to improve the activity of protein synthesis reactions.  
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By incorporating ATP/energy-regenerating systems, cell-free extracts can metabolize 
substrate supplements to survive for extended reaction periods, offering improved protein 
yields (247, 250-252).  Continuous exchange or bilayer systems that enable the diffusion 
of substrates into and byproducts out of a synthesis reaction boosts reaction productivity 
and lifetime (247, 253, 254).  By supplementing crude cell extracts with foldases, disulfide 
bond-forming enzymes, and chaperones, more complex proteins can be synthesized and 
properly folded with high yields.  Systematic optimization of the cell growth media, cell-
type, lysis method, buffer composition and other processing conditions can also lead to 
higher yields and improved extract activity. 
In contrast to the crude cell extracts which, although functional, contain a relatively 
unknown mixture of cellular parts that may vary from batch-to-batch, the PURE (“protein 
synthesis using recombinant elements”) cell-free expression system is a special protein 
synthesis platform made entirely of individually purified and reconstituted TX-TL 
components at defined concentrations (248, 255, 256).  The PURE system consists of 32 
polyhistidine-tagged translation factors, tRNA synthetases and other enzymes, each of 
which are over-expressed in separate E. coli cell lines, individuvally purified, then remixed 
at known quantities with ribosomes, buffer, tRNAs, NTPs, T7 RNA polymerase, and 
energy regeneration components (detailed composition given in (248, 256)).  This system 
is offered commercially, but at a considerably higher cost per reaction than other 
commercially available cell extract platforms.  Although the PURE system has a lower 
protein yield, it is still useful in many applications because it is a purified, fully 
characterized mixture and does not contain endogenous nucleases or proteases, which 
can degrade linear DNA templates, mRNA and protein products.  By implementing a 
continuous exchange platform, it was demonstrated that the protein yield of the PURE 
system could be markedly improved (254).  For cell-free expression reactions that require 
the formation of disulfide bonds to derive properly folded protein, simply by exchanging the 
PURE system’s reducing components for oxidized reagents and adding appropriate 
enzymes, antibodies can be successfully produced (256).  The versatility of the PURE 
system compared to crude cell extracts is also apparent by the substitution of fluorescently 
or radiolabelled tRNAs for visualization of product yield, the insertion of unnatural amino 
acids at specific positions by including modified tRNAs in the reaction mix, and the addition 
of various chaperones (ie DnaK, GroEL/GroES, DnaJ, GrpE, HrpA, Orn, TrxC, Tig, SlyD 
and PhnH) to enhance protein production, folding and activity (248, 257). 
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 The second most important consideration after selecting which cell-free system to 
use, is the design and construction of an appropriate DNA template for expression.  DNA 
templates can be exist as circular plasmids, linearized plasmids or linear PCR products, 
with preference towards using circular plasmids since they are resistant to exonucleases.  
By shielding linear DNA with DNA-binding proteins, protective sequence ends (245), or 
circularization, protein expression levels can be improved when expressing linear 
templates with crude cell extracts containing endogenous exonucleases.   Depending on 
whether a prokaryotic or eukaryotic cell extract is being used, specific sequence elements 
should be included in the DNA template.  DNA templates typically contain an IRES 
(internal ribosome entry site, found in viral mRNA that allows eukaryotic ribosomes to bind 
without a 5’cap) or Shine-Dalgarno (prokaryotic) sequence (both are ribosome binding 
sites or RBSs), Kozak (eukaryotic) sequence, and other appropriate promoters or 
enhancers in the 5’UTR (untranlated region, or leader seqeuence), affinity tags (258) at the 
N or C-terminus of the open reading frame (ORF), a poly-adenine stretch at the C-terminus 
to increase mRNA stability, and transcription terminator sequences in the 3’UTR.  Species-
independent translational sequences (SITS) have been developed to overcome 
translational inefficiency in eukaryotic-based cell extracts by including leader sequences 
which enable ribosome interactions even in the absence of 5’-capping (259).  Depending 
on which phage RNA polymerase is used (commonly T3, T7, or SP6) (260), the 
appropriate promoter sequence is necessary upstream of the start codon to enable 
transcription.  Phage RNA polymerases are frequently used in place of the extract-
endogenous version because of their high processivity, low error rates, and stringent 
promoter-specific activity.  In spite of their efficiency, bacteriophage RNA polymerases 
offer limited modularity or operator-gated regulation, but an E. coli RNA polymerase with 
sigma factor 70 system was found to provide yields comparable to phage-based 
transcription systems, while harnessing the larger repertoire of endogenous E. coli 
promoter/operator elements to enable construction of more complex synthetic genetic 
networks (261, 262). 
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Chapter 2:  
Asymmetric Polymerase Extension (APE) Gene 
Assembly 
 
2.1 Introduction 
 
To address the significant disconnect between commodity-scale DNA oligomer 
synthesis, gene assembly, and protein engineering, we began the development of a novel 
technique for constructing genes.  Originally, the gene assembly technique was subject to 
a set of requirements to facilitate its eventual application towards generating gene variants 
within a programmable microfluidic device that would also enable in vitro TX-TL, protein 
purification and characterization.  All of these experimental steps would be carried out 
within a single device for rapid, streamlined prototyping of new biological designs.  The 
original requirements for the gene assembly technique were the following: 
1) the ‘source’ DNA oligomers should be purchased at the most economical scale, with 
minimal purification steps, and with minimal genetic redundancy (sequence overlap) 
to minimize costs for generating multiple variants 
2) restriction or ligation enzymes should be avoided 
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3) the technique should be modular so that variants could be generated by substituting 
oligomer parts with distinct coding sequences, and also permit the production of 
repetitive sequences or gene parts with internal sequence homologies 
4) the assembly technique should display a low error rate, so that final gene products 
could be used directly, without error-correction processing steps, to generate 
functional, properly-folded proteins using the T7 RNA polymerase-based PURE TX-
TL system (255) 
5) the final gene assembly product should be compatible with microarray printing with 
minimal column or agarose gel purification steps 
These guidelines were used initially to direct the development of a gene assembly 
technique towards the construction of a complete, expression ready linear template 
encoding yeast enhanced GFP (yEGFP), and later used in the construction of zinc finger 
protein variants. 
 
 
2.2 Results 
 
As mentioned in Chapter 1.1, there exists a variety of techniques for constructing 
gene-length sequences from chemically synthesized DNA oligomers.  Since one of the 
primary requirements listed above obviates the use of ligase or restriction enzymes, we 
originally focused on developing a technique that used mesophilic strand-displacing 
polymerase (such as phi29 DNA polymerase, which functions at 30°C), or a mesophilic, 
non-strand displacing polymerase (such as DNA Pol I, Large Klenow Fragment from E. 
coli, which functions at 37°C, or T4 DNA polymerase, which functions at 12°C) with DNA 
chew-back to run multiple cycles of oligomer assembly.  Ideally, a substrate-bound primer 
would be used to anneal a longer oligomer gene part, extension would occur using a 
mesophilic DNA polymerase, the oligomer strand would be displaced/chewed-back at the 
5’-end with T7 exonuclease, and the 3’-end of the next oligomer in the assembly cycle 
would anneal to the exposed sequence, priming the next extension step.   
As a proof of concept, early method development focused on the use of oligomers 
making up the full linear expression template (including the 5’ and 3’UTR) for yEGFP 
(yeast enhanced green fluorescent protein; F64L, S65T), with the fluorescent protein 
coding sequence taken from the plasmid pKT127.  After comparing the fluorescence 
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obtained from four different linear templates using the PURExpress® In Vitro Protein 
synthesis kit (E6800, NEB), a design with a T7 terminator sequence, but without a poly-
adenine (polyA) tail, was selected (see Figure 2.2.1). 
 
Figure 2.2.1: (left) Gel image of PCR amplified yEGFP linear template variants prepared for cell-free 
expression using the PURExpress system.  (right) Graph of measured fluorescent output over time from 
batch, cell-free expression of each of the linear templates.  The variant without a polyA tail (EGFP-R1 
noPolyA, in blue) produced the highest level of fluorescence. 
 
This sequence (883 bp; full linear template sequence given in Figure 2.5.1) was 
partitioned into 13 oligomers (sequences given in Table 2.5.1).  The first 12 have a length 
of 90 nt, where 25 nt at the 3’-end of each is identical sequence to the 5’-end of the 
previous oligomer for annealing, and the last oligomer is 102 nt.  The 25 nt of sequence 
overlap for annealing was not adjusted to homogenize annealing temperatures, and so a 
range of annealing temperatures (from 47 to 59°C) existed.  If the overlapping regions had 
been modified using codon degeneracy to raise the annealing temperatures between 
oligomers while maintaining the proper protein coding sequence, the extension efficiency 
may have been improved.   
With 25 nt reserved for annealing, the incorporation of an oligomer brought 65 nt of 
new sequence in each assembly step, which satisfied the ‘minimal redundancy’ 
requirement for the assembly technique. Since APE is not an exponential amplification 
process, each annealing step consisted of warming a solution containing the bead-bound 
priming sequence with the appropriate oligomer to 75°C, then cooling down to room 
temperature prior to adding in polymerase for extension.  Shorter annealing regions could 
be used (20, 18, 16, 15, 10 and 5 nt overlaps were tested, with annealing temperatures of 
50, 47, 41, 38, 30 and 14°C, respectively), but since these lengths result in less stringent 
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annealing, higher error rates, and lower efficiency of oligomer incorporation, they were not 
used.  Overlaps below 15 nt were not capable of extending the annealed oligomer, which 
was also observed in a previously reported PCR assembly technique (263).   
A range of oligomer lengths were tested as well, including 155mer and 200mers 
(purchased as Ultramers® from Integrated DNA Technologies), again maintaining 25 nt of 
overlap with neighboring oligomers.  Although these oligomers offer a remarkably low level 
of sequence redundancy between addition steps, they were between 3-5 times more 
expensive (depending on synthesis scale) than 90mers because they are PAGE purified 
before being shipped.  Additionally, Ultramer® orders contained extremely low amounts of 
the full-length product (see Figure 2.2.2).  Due to these characteristics of Ultramers®, the 
gene assembly technique continued development with 90mers despite the less 
advantageous ratio of new sequence added in each assembly step.  The 90mers were 
purchased with only standard desalting, and so each full-length oligomer is also 
contaminated with truncated products that result during column-based synthesis (see 
Figure 2.2.2).  Due to the amount of truncated products found even in synthesized 90mer 
products, by utilizing a PCR purification kit to selectively remove oligomers shorter than 40 
nt, the efficiency of annealing and extension reactions was improved (Figure 2.2.3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.2 : Agarose gel image of single stranded DNA oligomers (ssDNA) of varying lengths.  Ultramer® 
synthesis products offer very little full-length product (barely visible bands above 100bp ladder marker) 
compared to shorter oligomers.  Even with PAGE purification, there is a large streak of truncated oligomers 
present in Ultramer® products. 
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Figure 2.2.3 : Agarose gel image of 90 nt, single stranded DNA oligomers (ssDNA) before and after column 
purification to eliminate truncated synthesis products. 
 
 
The T7 exonuclease chew-back reaction of the assembly cycle was difficult to 
optimize, and as a result, was replaced by an isothermal, ambient temperature, alkaline 
denaturation step (264).  The excess of hydroxide ions in basic solutions (pH > 7) shields 
hydrogen bond formation between complementary strands of DNA, resulting in strand 
separation.  This method was found to be particularly robust for dissociating DNA strands, 
and was easily incorporated into the gene assembly technique.  A sodium hydroxide 
solution (NaOH, 0.15M) in water was used for all dissociation steps.   
After comparing the activity of T4 DNA Polymerase and DNA Polymerase I, Large 
Klenow Fragment (5’?3’ exo-, E. coli; NEB) for extension, we decided to continue only 
with DNA Polymerase I since it appeared to have better success at producing product.  
The original extension process was run for 30 minutes at room temperature or 30°C with 
one unit of DNA Pol I.  Due to this long incubation time, the extension reaction limited the 
number of extension steps that could be performed in a day.  Although DNA Pol I has a 
relatively high error rate compared to other high-fidelity polymerases, we were originally 
interested in developing an isothermal assembly process, and so we continued using DNA 
Pol I.
 To facilitate a modular gene assembly technique, the process requires a solid 
substrate from which to ‘grow’ a gene by sequential addition of oligomers.  The use of a 
solid-phase technique would also enable the in situ assembly of unique gene products 
within separated reaction chambers on a microfluidic device like MITOMI, and also provide 
the option of preparing large libraries of gene variants using automated liquid-handling 
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robotic systems.  After experimenting with four varieties of streptavidin-coated magnetic 
beads (Dynabeads®, Invitrogen), we chose to use the MyOne™ Streptavidin T1 beads on 
the basis that they have the smallest diameter (1 μm), are specifically used for 
protein/nucleic acid applications, and due to their small diameter, have an increased 
binding capacity and lower sedimentation rate compared to the other varieties available.  
For the gene assembly technique, the first step in the process is incubating a volume of 
the T1 beads with a solution containing biotinylated ‘initiator’ oligomer, which anneals to 
the first oligomer in the assembly sequence.  The initiator oligomer contains sequence 
from the 5’ terminus of the antisense strand, and the first extension oligomer codes for the 
3’ terminus of the sense strand.  In this way, the gene is assembled from what will become 
the C-terminus of the protein.   
Since column synthesized oligomers are produced from 3’ to 5’, if truncated 
products are formed, they lack the 5’-terminal nucleotides.   Since our assembly technique 
assembles the sense strand from the 3’-terminus, each extension step preferentially 
incorporates the next oligomer only if the previous step used a full-length oligomer, and 
therefore provides a full 25 nt of overlap for annealing (see Figure 2.2.4). 
 
Figure 2.2.4 : Cartoon illustrating the selective incorporation and extension of full-length oligomers compared 
to truncated synthesis products. 
 
To determine the limits of DNA crowding or extent of steric hindrance on the bead 
surface, a variety of bead volumes were incubated with the ssDNA, biotinylated initiator 
oligomer, but also with a range of dsDNA PCR products with one 5’-biotinylated strand 
(see Figure 2.2.5).  The concentrations of the DNA products being tested were measured 
using a NanoDrop, and equal volumes of the DNA were incubated with different volumes 
of beads.  After incubation, the beads were pelleted by magnetism, the supernatant was 
collected, and the DNA concentration was measured again to determine the amount of 
DNA remaining in the sample volume.  The DNA bound to the beads was eluted by boiling 
the beads in water with 0.1% (v/v) SDS (sodium dodecyl sulfate), which disrupts the 
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streptavidin-biotin interaction, freeing the DNA from the bead surface.  This eluate was 
then also measured to determine the DNA concentration.  Due to limitations in the 
detection sensitivity of the NanoDrop, very small variations in DNA concentration were not 
detectable, but in general, the DNA mass balance was maintained (black lines in top part 
of Figure 2.2.5): pmol?DNAtotal ? pmol?DNAbound to beads ? pmol?DNAin supernatant  
 
 
 
Figure 2.2.5 : Evaluating steric hindrance effects on streptavidin-coated magnetic beads as a function of 
DNA length. (Top) DNA saturation experiments using different bead volumes to determine the maximum 
amount of DNA that be bound as a function of DNA lengths. (Bottom) Summary of the amount of DNA eluted 
from beads after boiling. 
 
0 10 20 30 40 50
0
100
200
300
400
Bead volume
D
N
A
 (p
m
ol
)
biotin-initiator oligo (ssDNA, 18nt)
DNA unbound
DNA released by beads
Total DNA
Total DNA expected
0 10 20 30 40 50
0
2
4
6
8
10
505 bp dsDNA
Bead volume
D
N
A
 (p
m
ol
)
0 10 20 30 40 50
0
5
10
15
20
25
155 bp dsDNA
Bead volume
D
N
A
 (p
m
ol
)
0 10 20 30 40 50
0
1
2
3
4
5
883 bp (EGFP) dsDNA
Bead volume
D
N
A
 (p
m
ol
)
Comparison of DNA binding capacities
0 10 20 30 40 50
1
10
100
1000
Bead volume
D
N
A
 e
lu
te
d 
(p
m
ol
)
Effect of DNA length on pmol bound (eluted)
18mer
155mer
505mer
883mer
3.4 pmol
expt (3pmol)
0 10 20 30 40 50
104
105
106
107
Bead volume
D
N
A
 e
lu
te
d 
(m
ol
ec
ul
es
/b
ea
d)
Effect of DNA length on # molecules bound (eluted)
18mer
155mer
505mer
883mer (EGFP)
4.1x104 molecules
expt 7.2x104 molecules 
per bead
? 46 
By examining the effect of DNA length on the maximum amount of DNA bound per 
bead volume, it was determined that in order to provide sufficient space on 25 μL of beads 
to assemble a yEGFP gene, the initiator oligomer needed to be present at the same 
density, which was determined to be 3.4 pmol, which corresponds to roughly than 1.3% 
bead coverage using the initiator oligomer (Figure 2.2.5).  This starting density was used 
for all subsequent gene assembly experiments (0.6 μL of 5 μM biotinylated initiator 
oligomer per 25 μL of beads). 
 To evaluate the successful annealing and extension of the yEGFP linear template, a 
set of ‘checking’ primers (see Table 2.5.1 for sequences; amplified products in Figure 
2.2.6) were designed such that bead-bound extensions or SDS-eluted products could be 
amplified by PCR and visualized by gel electrophoresis.  Each ‘check’ PCR utilized a 
primer with sequence identical to the biotinylated-initiator oligomer (but without biotin 
group) in combination with the primer needed to anneal at the extension step of interest.  
The efficiency of multiple extension reactions was improved, and amplification (‘check’ 
PCR) of yEGFP gene assembly was found to work for up to 9 rounds of extension (Figure 
2.2.6). 
 
Figure 2.2.6 : Agarose gel image demonstrating that up to 9 consecutive steps of APE assembly can be 
achieved.  Each band is the ‘checking’ PCR amplification product from a different APE reaction pool that was 
periodically sampled to evaluate successful extension. 
 
It was not clear why the assembly process was not capable of functioning beyond 9 
extension steps.  It is possible that the incorporation of truncated oligomer synthesis 
products may have depleted the available annealing sites on the bead surface, or that 
steric hindrance effects were reducing the efficiency of the remaining assembly reactions.  
Additionally, each extension step was performed at 30°C, so it is possible that secondary 
structure of oligomers in later steps prevented them from being incorporated. 
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 The assembly of a linear expression template for yEGFP was useful as a proof-of-
concept for development of the asymmetric polymerase extension (APE) method.  Since 
the intention was to eventually establish a pipeline for rapid protein engineering, and the 
set of protein variants that could be made from EGFP (265, 266) were not particularly 
interesting from a synthetic biology or genetic network perspective, we shifted our focus 
from fluorescent proteins to zinc finger proteins.  This shift was primarily motivated by the 
fact that we had established our solid-phase assembly technique was functional for up to 
nine consecutive extension steps (610 bp), using DNA Pol I (Large Klenow Fragment) for 
extension, 90 nt long oligomers with 25 nt overlaps, and NaOH strand dissociation.   
As mentioned in Chapter 1.3, C2H2 zinc finger (ZF) proteins are relatively compact 
protein domains, consisting of about 30 amino acids, which can be easily encoded within a 
single 90 nt oligomer.  Zinc finger arrays (ZFAs), which recognize longer DNA target sites, 
can be produced by concatenating several ZF domains using artificial or naturally derived 
peptide linkers.  Databases of ZF domain sequences and their consensus targets (146), 
crystal structures, as well as target prediction algorithms (76), are readily available after 
two decades of ZF research.  Additionally, the MITOMI microfluidic device is an ideal tool 
for characterizing protein-DNA interactions.  From these conclusions, we decided to 
pursue ZFA engineering as a proof-of-concept for our rapid protein engineering pipeline, 
and began to adapt the gene assembly protocol towards this application. 
Since canonical ZF binding relies on the amino acid residues in positions -1 to 6 of 
the α-helix to dictate DNA target specificity, only these residues were changed to create 
ZFA variants that recognize specific DNA target sites.  Other parts of the protein that are 
indirectly involved in DNA sequence recognition, called the framework, were taken directly 
from the three-finger murine transcription factor Zif268 (RCSB PBD 1AAY).  The Zif268 
coding sequence (90 aa) was converted to an E. coli (strain K12) codon optimized 
nucleotide sequence using JCat (Java Codon Adaptation Tool (267), www.jcat.de).  The 
resulting 270 nt sequence was then partitioned into 5 oligomers: 3 ‘finger’ oligomers, each 
containing the sequence coding for α-helix residues with flanking regions, and 2 ‘linking’ 
oligomers containing sequences bridging the three ‘finger’ oligomers (Figure 2.2.7).  Each 
oligomer has a 25 or 28 nt overlap with the oligomer preceding it for annealing. This way, 
all oligomers with the appropriate flanking sequence can be interchanged with each other 
since they contain the necessary complementary sequence for annealing.  This allows 
single oligomers to be used in multiple zinc finger assemblies, but limits them to the same 
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position in the assembly process.  Linking oligomers ‘Link3-2’ and ‘Link2-1’ are used for all 
assemblies, whereas libraries of O1F3 (Oligo1 Finger3), O3F2 (Oligo3 Finger2) and O5F1 
(Oligo5 Finger1) oligos are used to generate different 3-finger assemblies (21 nt located in 
the colored regions of Figure 2.2.7).  Oligomers were ordered from IDT (sequences given 
in Table 2.5.2) with standard desalting only and were rehydrated to 500 μM in 1x Tris-
EDTA (TE) buffer for stock solutions, and diluted to 50 μM with PCR grade water for 
working solutions. 
Only the three oligomers coding for the sequence variants must be ordered for each 
unique gene assembly, and since these are below the 90 nt pricing and synthesis scale 
threshold for oligomers ordered through IDT, they contain higher amounts of full-length 
product, and do not require column purification for APE assembly.  Unlike the EGFP 
assembly oligomers, the five oligomers needed for ZFA assembly do not code for the 
entire linear, expression-ready template.  APE assembly was used to generate the ZFA 
variants only, while other DNA parts needed for expression (5’ and 3’ UTR, affinity tag) are 
introduced downstream in PCR reactions.  
 
 
Figure 2.2.7 : Schematic of the oligomers used in APE assembly of tridactyl zinc finger transcription factors. 
Generic sequences are given in Supplementary Table 1.  Synthesis occurs from the 3’-end of the sense 
strand (Finger3) to the 5’-end (Finger1).  O1F3, O3F2, and O5F1 are unique oligos with 21 nt in the colored 
regions coding for recognition helix variants that target different DNA triplets.  Link3-2 and Link2-1 are 
universal, and used in all APE assemblies. 
 
To evaluate if functional ZFAs could be produced with APE assembly, oligomers 
were designed (Table 2.5.3) to express the unique specificity residues from wildtype 
Zif268 protein in addition to three artificial ZFA proteins (37-12, 92-1, 158-2) from a recent 
publication (156).  These ZFAs were selected because their DNA-binding specificity had 
already been evaluated experimentally and would serve as ideal controls for our first 
experiments.  We began by preparing gene assemblies for each of these ZFA variants 
using APE, and then developed a set PCRs to add on the remaining sequence needed to 
prepare linear templates for expression using the PURExpress system. 
seed O1F3 = 74nt Link3-2 = 60nt
O3F2 = 77nt
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? 49 
 Prior to beginning cell-free expression experiments, the error-rate of the 5-step APE 
assembly was evaluated.  APE assembly was carried out using either DNA Polymerase I, 
(Large Klenow Fragment; NEB) for reactions carried out entirely at room temperature, or 
Phusion High-Fidelity Polymerase (NEB) with brief annealing and extension steps on a 
thermal cycler.  Both approaches used unpurified oligomers for the construction of ZFA 
variant 92-1 within a Zif268 backbone (framework).  The assembly from each APE reaction 
was amplified by PCR using a high-fidelity polymerase.   
Due to the formation of incomplete extension products during APE assembly 
rounds, PCR amplification can lead to the formation of multiple non-specific bands.  To 
overcome this problem, we developed a modified band-stab technique (268) to isolate the 
band of interest, and reamplifyed it to reduce the amount of nonspecific products in 
downstream steps.  This technique was performed on both the Klenow/room-temperature 
assembly and Phusion/thermocycled assembly PCR products.  The resulting linear 
templates from the re-amplified band-stab products, in addition to the products from the 
Phusion assembly without band-stab, were cloned via Gibson assembly and transformed.   
Colony PCR was used to verify clones with the expected size insert, and 32 clones 
from each assembly (Klenow +band-stab, Phusion +band-stab, and Phusion −band-stab) 
were sent for Sanger sequencing.  The error rate of APE synthesis was determined by 
summing the frequency of all deletions, insertions and substitutions, then dividing the total 
number of error events by the total kilobases of interest (amplified PCR insert = 239 bp × # 
of clones with successful sequencing).  The results of this analysis (Table 2.2.1) prompted 
the continued use of the high-fidelity Phusion polymerase with short annealing steps for all 
future APE assembly reaction.  The band-stab step preparation did not appear to have any 
improvement on the error-rate when Phusion polymerase was used (0.785 errors/kb).  We 
evaluated how the APE assembly error-rate compares with previously published gene-
assembly techniques (Figure 2.2.8; Table 2.5.4), and it performs as well or better than the 
majority of other methods without the need for error-correction steps.   
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Table 2.2.1 : Error rate analysis for APE assembly 
ZF synthesis 
method 
(polymerase used 
for extension) 
# of full-
length 
sequence 
reads (out 
of 32) 
Total kb of 
interest 
sequenced 
# deletion 
events 
# insertion 
events 
# substitution 
events 
Total error 
events 
Error/kb 
Phusion  
-band stab 
32 7.648 4 2 0 6 0.785 
Phusion  
+band stab 
32 7.648 5 0 1 6 0.785 
Klenow  
+band stab 
28 6.692 15 1 1 17 2.54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.8: Comparison of APE error rate with values from previously published gene assembly 
techniques. A line between two points indicates a range of error rates from different experimental conditions. 
 
To optimize the ZFA templates for on-chip expression, we fused the ZFA 
assemblies to a C-terminal EGFP domain using a short, but rigid, proline-alanine linker by 
PCR (full sequence of Zif268 linear template in Figure 2.5.2; oligomer sequences in Table 
2.5.5).  The EGFP domain is useful for enabling fluorescent confirmation of protein 
production during cell-free expression, but was also used as an affinity tag for selective 
purification of properly transcribed and translated product, and as a tool for quantifying the 
amount of protein trapped during microfluidic analysis with MITOMI.  The final APE 
assembly process for ZFA engineering is illustrated in Figure 2.2.9, along with a timeline 
for array printing and operation of the MITOMI assays. 
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Figure 2.2.9 : (Left) Schematic of the APE solid-phase gene assembly technique, showing assembly through 
the first two extension steps. (Right) Process timeline from gene assembly to protein characterization. 
 
 
2.3 Discussion 
 
In Chapter 2, we discuss the development of a novel, solid-phase gene assembly 
technique, first for the construction of yEGFP, and later applied towards the construction of 
ZFA variants.  By evaluating the error rate of assembly using both DNA Pol I (Large 
Klenow Fragment) and Phusion polymerase, we were able to optimize the assembly 
process.  The highest error rate was observed in the colonies cloned with the Klenow APE 
assembly method.  Since the EGFP affinity tag is appended to the assembly product by 
PCR, the majority of these products would have resulted in nonfunctional ZFAs, since they 
code for early stop codons or introduce frame-shifts which would prevent the EGFP tag 
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from folding and being immunoprecipitated in a MITOMI experiment.  In this manner, even 
truncated/non-specific PCR products that are formed during the final steps of linear 
template preparation are not problematic, since those products will not be included in the 
DNA target binding analysis.  The Phusion APE assembly products yielded significantly 
lower erroneous sequences, with no effect seen from the band-stab PCR.  The high error 
rate seen in the DNA Pol I (Large Klenow Fragment) reaction product can be partly 
explained by comparing the relative error rates documented for Klenow (0.018 errors/kb, 
due to removal of 5’?3’ exonuclease) and Phusion (0.00044 errors/kb) polymerases.  
Additionally, since the Phusion-based assembly technique required brief annealing steps 
at elevated temperatures while the Klenow-based technique was performed at room-
temperature, one can reasonably expect that the high-temperature annealing improved the 
stringency of oligomer incorporation.   
 Although APE assembly was found to be limited to 9 consecutive extension steps 
(610 bp), this length of sequence is more than adequate for the assembly of ZFA variants. 
To overcome this length limitation of APE assembly and construct longer genetic parts, it 
would be possible to begin multiple APE assembly reactions in parallel, then use PCR to 
assemble the products from each of these reactions towards the construction of gene 
parts larger than 1 kb.  The true power of the APE assembly method lies in its ability to 
generate genetic parts with high variability or repetitive motifs, followed by conventional 
PCR to introduce the constant regions of the gene, which are unchanged across variants.  
Since the oligomers are added sequentially and unincorporated DNA is separated from the 
bead-bound strands during buffer exchange steps, the APE assembly technique offers a 
lower risk of chimeric product formation compared to one-pot ligase or PCA-based 
assembly techniques.  Column-synthesized oligomers can be used directly without 
purification, and the final, PCR amplified linear template can be used directly for 
microarray printing and on-chip expression.  Since the assembly technique is magnetic-
bead based, it is amenable to scale-up with automated liquid handling platforms.      
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2.4 Methods 
 
2.4.1 Asymmetric primer extension (APE) assembly 
 
Prior to gene-assembly, an aliquot (800-1200 μL) of MyOne™ Streptavidin T1 
beads (Life Technologies) are placed in a 1.5 mL Eppendorf tube, pelleted using a 
magnetic stand, and resuspended in an equivalent volume of 0.2M NaOH in water.  The 
beads are preconditioned for at least 1 hour at room temperature before use, then stored 
at 4°C for longer conditioning times.  These conditioned beads can be used for up to one 
month after being suspended in the 0.2M NaOH solution.  It was previously found that 
preconditioning of beads in NaOH releases labile streptavidin monomers (269), and in our 
hands this translated to a reduction in non-specific PCR bands during intermediate quality 
control PCR steps and during amplification of the final assembly. Each individual assembly 
reaction requires 25 μL of preconditioned beads. Lower bead quantities may work as well, 
but to account for losses during washing, buffer exchanges and transfer steps, we have 
continued using 25 μL with consistent success.  Larger reactions are also possible by 
scaling all volumes accordingly.  This is particularly useful during the creation of zinc finger 
combinatoric array variants. By starting with a large pool of beads, beginning the assembly 
together with the same Oligo1Fin3 and Link3-2, followed by partitioning the pool into 
smaller volumes and continuing assembly with different Oligo3Fin2 parts in separated 
reactions, followed by a final partitioning for Oligo5Fin1 parts, where the final volume in 
each Oligo5Fin1 assembly is 25 μL, many different genes can be assembled within the 
same workflow. 
For a single APE reaction, 25 μL of preconditioned beads are pelleted using a 
magnetic stand (Invitrogen DynaMag™-Spin) for 30-60s until the solution is clear. The 
supernatant (0.2M NaOH) is carefully aspirated.  The beads are then washed twice with 25 
μL of 1x binding and washing buffer (B&W; 2x contains 10mM Tris-HCl pH 7.5, 1mM 
EDTA, 2M NaCl) containing 0.01% (v/v) Tween20 (BW+Tween; to reduce non-specific 
binding (270)).  Each washing step involves adding the wash solution, mixing the solution 
by aspiration until the beads are resuspended, then pelleting the beads and removing the 
supernatant.  Then the beads are pelleted again and resuspended in 25 μL of 2x B&W 
Buffer (without Tween20), to which 25 μL of ‘seed’ oligomer solution (0.12 μM biotinylated 
seed oligomer in PCR grade water; Supplementary Table 1) is added and mixed.  This 
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mixture is incubated at room temperature for at least 15 minutes on a lab rotisserie.  
Following incubation, the beads are pelleted against the magnetic stand, washed twice 
with 25 μL of 1x HF Buffer without detergent (Phusion® HF Buffer Detergent-free (5x), 
New England Biolabs) to prevent bubble formation during resuspension, and finally 
resuspended in 25 μL Oligo1Fin3 extension mix (final concentrations: 1x HF Buffer with 
detergent, 0.2 mM dNTPs, 5% DMSO, 8 μM Oligo1Fin3, 0.3 units Phusion High-Fidelity 
Polymerase (NEB)).   
This mixture is then placed on a thermocycler and run through a brief annealing and 
extension routine (5.5min at Tanneal, 2min at 72°C, then hold at 25°C; Tanneal for each 
oligomer is given in Fig. 2.2.7).  The tube is removed from the thermocycler, the beads are 
pelleted, and the supernatant is removed and discarded.  The beads are then washed 
twice with 50 μL 1x SSC buffer (saline sodium citrate, Sigma), resuspended in 50 μL 
0.15M NaOH and incubated at room temperature on a rotisserie for 10 minutes to facilitate 
strand dissociation.  The beads are then pelleted, the supernatant is removed, and the 
beads are washed once with 50 μL 0.15M NaOH, once with 50 μL 1x BW+Tween, and 
once with 50 μL 1x HF buffer without detergent.  The beads are then resuspended in 
Oligo2 (Link3-2) extension mix (same recipe as for Oligo1, except Link3-2 is used), then 
placed back on the thermocycler, and run through the annealing and extension routine, 
where Tanneal has been adjusted to the temperature required for this annealing reaction. 
This procedure of extension, strand dissociation via 0.15 M NaOH, and buffer exchanges 
is repeated for each oligomer in the assembly.  After the final extension reaction 
(Oligo5Fin1), there is no NaOH dissociation step.  Instead, the beads are pelleted, washed 
twice with 50 μL 1x SSC buffer, and resuspended in a final volume of 20 μL 10 mM Tris-Cl 
pH 8.5 buffer.   
The beads in Tris-Cl buffer from the final extension step are used directly as 
template for a PCR amplification of the complete 5-step assembly product.  PCR primers 
were designed to amplify the 239 bp product (Table 2.5.2).  For a 20 μL PCR reaction, 
final concentrations are as follows: 1x HF Buffer with detergent (New England Biolabs), 
0.2mM dNTPs, 5% DMSO, 0.5 μM each primer (assembly check-f and –r), 0.6 μL 
suspension of beads in Tris-Cl (template), 0.3 units Phusion High-Fidelity Polymerase; 
touchdown PCR: 98°C, 30s; 74>72°C, 30s then 17 cycles at 71°C, 30s ; 72°C, 30s).  4 μL 
of this PCR is then run on a 2% agarose gel with 0.4x GelGreen (Biotium) at 110V for 1h.  
Due to non-specific primer interactions with the template and interactions with truncated 
? 55 
assembly products, some PCR amplifications can result in the formation of multiple 
truncated bands, the highest of which is the complete assembly product. To overcome this 
problem, we have taken advantage of a modified band-stab technique a(268) to isolate the 
band of interest and re-amplifying it to reduce the amount of nonspecific products in 
downstream steps.  Briefly, the 2% gel is imaged using a blue-light transilluminator and the 
band of interest is captured using a 200 μL pipette tip, with the end cut off about 1 cm from 
the tip, by stabbing into the gel at the location of the band.  The pipette tip is then placed 
into a 1 mL Eppendorf tube, and the agarose gel core inside the pipette tip is pushed out 
using a second sterile pipette tip.  20 μL of Qiagen EB buffer (10 mM Tris-Cl, pH 8.5) is 
added to the agarose gel sample, briefly vortexed, centrifuged, and incubated at 80°C for 
at least 10 minutes with the tube cap closed.  The sample is then vortexed and centrifuged 
again, before a 0.25 μL sample of the buffer is taken as template for a second PCR 
amplification.  This PCR is prepared and thermocycled following the same recipe from the 
first PCR (assembly check PCR; Figure 2.5.3). 
 
 
2.4.2 Expression-ready linear template preparation 
 
Following the second assembly check PCR, the core region coding for the three 
linked a-helices is complete, but the final template will consist of a C-terminal proline-linker 
and EGFP fusion, a 6x histidine tag, and 5’ and 3’ UTRs for expression within a cell-free, 
transcription/translation mixture.  All of these parts are added to the zinc-finger assembly 
via 4 different PCRs: a fusion PCR (for adding the proline-linker, EGFP domain, and 6x-
histidine tag; results in a 1019bp product), a gene-specific PCR (for adding part of the 5’ 
and 3’ UTRs; results in a 1084bp product), and an extension+final 2-step PCR (which 
completes the template construction and amplifies the full-length product of 1192bp; 
oligomer sequences in Table 2.5.5).  The fusion PCR requires two templates: the 239bp 
zinc-finger construct and a previously amplified EGFP domain from the pKT127 plasmid, 
including a 5’-proline linker and 3’-6x histidine tag.  Briefly, in a 20 μL PCR containing 1x 
HF Buffer with detergent, 0.2 mM dNTPs, 5% DMSO, 0.5 μM each primer (Prolinker-
EGFP-f and EGFP-6His-r), 1 ng of pKT127, and 0.3 units Phusion High-Fidelity 
Polymerase are thermocycled for 25 cycles (98°C, 30s; 61.7°C, 30s; 72°C, 1min).   
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This product (Prolink-EGFP-6His, 805nt) is used without purification in the fusion 
PCR.  The fusion PCR is carried out in 2 steps, the first reaction contains all the necessary 
ingredients for PCR except the nucleotide mix and polymerase.  A 15 μL reaction is 
prepared containing 1x HF Buffer with detergent, 5% DMSO, 0.5 μM of each primer 
(assembly check-f and EGFP-6His-r), and 0.25 μL each of the assembly PCR from band-
stab and Prolink-EGFP-6His PCR.  This mixture is placed on a thermocycler and heated to 
98°C for 4min, then cooled down (10% ramp) to 25°C for annealing.  Then 5 μL of an 
extension mixture (1x HF Buffer with detergent, 0.2 mM dNTPs, 0.3 units Phusion) is 
spiked into the annealing mixture (20 μL total) and cycled 20 times (98°C, 30s; 72°C, 30s; 
72°C, 1min).  The gene-specific PCR uses the product generated in the fusion PCR as 
template.  A 20 μL reaction is prepared: 1x HF Buffer with detergent, 0.2 mM dNTPs, 5% 
DMSO, 0.5 μM each primer (genespecific-f and EGFP-6His-r), 0.25 μL of the fusion PCR, 
and 0.3 units Phusion polymerase.  This reaction is cycled using a short touchdown PCR 
(98°C, 30s; 75>72°C, 30s; 72°C, 1min), followed by 16 cycles (98°C, 30s; 72°C, 30s; 
72°C, 1min).  The 2-step extension+final PCR uses the product generated in the gene-
specific PCR as template.  In this reaction, it is very important to use the HF Buffer without 
detergent, since this product will be used directly for microarray spotting and the presence 
of detergent will result in large spots.  A 20 μL reaction is prepared: 1x HF Buffer without 
detergent, 0.2 mM dNTPs, 5% DMSO, 2.5 nM each primer (extension-f and -r), 0.25 μL of 
1:10 diluted gene-specific PCR (in Tris-Cl or water), and 0.3 units Phusion polymerase.  
This mixture is thermocycled 10 times (98°C, 30s; 61°C, 30s; 72°C, 1min).  Then the 
reaction is kept at 72°C for 2 minutes, and cooled to 25°C.  At this point, 0.1 μL of each 
final_highTm primer (50 μM stock; final 0.25 μM in 20.2 μL) are spiked into the mixture, 
and it is thermocycled again via a short touchdown PCR, 98°C, 30s; 75>72°C, 30s; 72°C, 
1min, then 20 cycles 98°C, 30s; 71°C, 30s; 72°C, 1min.  Successful amplification is 
determined by running 1.5 μL of the product on a 1% agarose gel, and checking for the 
1192bp product (see Figure 2.5.3). 
 
 
2.4.3 Error Rate Analysis 
 
Gene synthesis reaction on beads was carried out using either DNA Polymerase I, 
Large (Klenow) Fragment (NEB) for APE assembly reactions entirely carried out at room 
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temperature, or Phusion High-Fidelity Polymerase with brief annealing and extension 
steps on a thermal cycler.  Both approaches used unpurified oligomers for the construction 
of zinc finger array 92-1 within a Zif268 backbone.  For Klenow assembly error analysis, 
following 20 cycles of PCR using Phusion polymerase for amplification of template 
detached from beads using an SDS-boiling and reannealing protocol, the reaction was run 
on an agarose gel and the product band was gel-stabbed, and a second PCR (20 cycles 
with Phusion polymerase) was run.  For Phusion assembly error analysis, following 20 
cycles of PCR using Phusion polymerase for amplification of the template attached to 
beads in 1x SSC buffer, the reaction was run on an agarose gel and the product band was 
gel-stabbed, and a second PCR (20 cycles) was run.  The PCR product (239bp) from each 
of the band-stab PCRs was purified and cloned via Gibson assembly into the pUC19 
plasmid with assembly-check overhangs.  In addition, the PCR from the Phusion assembly 
was used without the band-stab procedure, to determine whether the band-stab has an 
effect on error rate. 
Chemically competent DH5α E. coli cell aliquots (30 μL) were transformed with 1.5 
μL of each Gibson assembly product via heat shock (30s at 42°C), recovered in 300μl 
SOC medium for 1 hour at 37°C, and plated on ampicillin plates for overnight growth at 
37°C.  Colonies from each plate (Klenow+band stab, Phusion+band stab, Phusion no 
stab) were picked with a sterile 200 μL pipette tip, briefly stirred in 20 μL PCR-grade water, 
boiled for 15min, and centrifuged.  Water from the colony boils was used as template for 
an insert-check PCR using the primers pUC19-f and pUC19-r with Phusion polymerase.  
All of these PCR reactions were run on 1.5% agarose gels with GelRed to determine which 
colonies had the correct sized insert.  Colonies were picked and analyzed in this way until 
32 colony PCRs for each assembly method were identified with a single band 
corresponding to the correct sized insert.  The insert-check PCRs were submitted for 
Sanger sequencing in a 96-well plate without PCR cleanup (Microsynth AG), and the 
resulting sequencing reads were aligned with the expected sequence to analyze the error-
rate and identify which types of errors were prevalent. 
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2.5 Supplementary Figures and Tables 
 
 
 
Figure 2.5.1: Complete sequence of expression-ready linear template for yEGFP, which was used to design 
oligomers for development of asymmetric polymerase extension (APE) assembly. 
 
 
 
 
 
 
 
 
               5'final primer              T7 promoter                                                                  RBS       
               |                           |                                                                            |
gat ctt aag gct aga gta cTA ATA CGA CTC ACT ATA GGG AGA CCA CAA CGG TTT CCC TCT AGA AAT AAT TTT GTT TAA Ctt aag aag gag gaa aaa aaa a <100
                                                                                                                                    M
cta gaa ttc cga tct cat gAT TAT GCT GAG TGA TAT CCC TCT GGT GTT GCC AAA GGG AGA TCT TTA TTA AAA CAA ATT Gaa ttc ttc ctc ctt ttt ttt t
            10           20           30            40           50           60            70           80           90 
 
tg tct aaa ggt gaa gaa tta ttc act ggt gtt gtc cca att ttg gtt gaa tta gat ggt gat gtt aat ggt cac aaa ttt tct gtc tcc ggt gaa ggt ga <200
   S   K   G   E   E   L   F   T   G   V   V   P   I   L   V   E   L   D   G   D   V   N   G   H   K   F   S   V   S   G   E   G   E 
ac aga ttt cca ctt ctt aat aag tga cca caa cag ggt taa aac caa ctt aat cta cca cta caa tta cca gtg ttt aaa aga cag agg cca ctt cca ct
            110          120           130          140          150           160          170          180           190 
 
a ggt gat gct act tac ggt aaa ttg acc tta aaa ttt att tgt act act ggt aaa ttg cca gtt cca tgg cca acc tta gtc act act tta act tat ggt <300
  G   D   A   T   Y   G   K   L   T   L   K   F   I   C   T   T   G   K   L   P   V   P   W   P   T   L   V   T   T   L   T   Y   G   
t cca cta cga tga atg cca ttt aac tgg aat ttt aaa taa aca tga tga cca ttt aac ggt caa ggt acc ggt tgg aat cag tga tga aat tga ata cca
            210          220          230          240           250          260          270           280          290 
 
gtt caa tgt ttt tct aga tac cca gat cat atg aaa caa cat gac ttt ttc aag tct gcc atg cca gaa ggt tat gtt caa gaa aga act att ttt ttc a <400
V   Q   C   F   S   R   Y   P   D   H   M   K   Q   H   D   F   F   K   S   A   M   P   E   G   Y   V   Q   E   R   T   I   F   F   K
caa gtt aca aaa aga tct atg ggt cta gta tac ttt gtt gta ctg aaa aag ttc aga cgg tac ggt ctt cca ata caa gtt ctt tct tga taa aaa aag t
            310          320          330           340          350          360           370          380          390 
                                                                               enhancedGFP       
                                                                               |
aa gat gac ggt aac tac aag acc aga gct gaa gtc aag ttt gaa ggt gat acc tta gtt aat aga atc gaa tta aaa ggt att gat ttt aaa gaa gat gg <500
   D   D   G   N   Y   K   T   R   A   E   V   K   F   E   G   D   T   L   V   N   R   I   E   L   K   G   I   D   F   K   E   D   G 
tt cta ctg cca ttg atg ttc tgg tct cga ctt cag ttc aaa ctt cca cta tgg aat caa tta tct tag ctt aat ttt cca taa cta aaa ttt ctt cta cc
            410          420           430          440          450           460          470          480           490 
 
t aac att tta ggt cac aaa ttg gaa tac aac tat aac tct cac aat gtt tac atc atg gct gac aaa caa aag aat ggt atc aaa gtt aac ttc aaa att <600
  N   I   L   G   H   K   L   E   Y   N   Y   N   S   H   N   V   Y   I   M   A   D   K   Q   K   N   G   I   K   V   N   F   K   I   
a ttg taa aat cca gtg ttt aac ctt atg ttg ata ttg aga gtg tta caa atg tag tac cga ctg ttt gtt ttc tta cca tag ttt caa ttg aag ttt taa
            510          520          530          540           550          560          570           580          590 
 
aga cac aac att gaa gat ggt tct gtt caa tta gct gac cat tat caa caa aat act cca att ggt gat ggt cca gtc ttg tta cca gac aac cat tac t <700
R   H   N   I   E   D   G   S   V   Q   L   A   D   H   Y   Q   Q   N   T   P   I   G   D   G   P   V   L   L   P   D   N   H   Y   L
tct gtg ttg taa ctt cta cca aga caa gtt aat cga ctg gta ata gtt gtt tta tga ggt taa cca cta cca ggt cag aac aat ggt ctg ttg gta atg a
            610          620          630           640          650          660           670          680          690 
 
ta tcc act caa tct gcc tta tcc aaa gat cca aac gaa aag aga gac cac atg gtc ttg tta gaa ttt gtt act gct gct ggt att acC CAT GGT ATG GA <800
   S   T   Q   S   A   L   S   K   D   P   N   E   K   R   D   H   M   V   L   L   E   F   V   T   A   A   G   I   T   H   G   M   D 
at agg tga gtt aga cgg aat agg ttt cta ggt ttg ctt ttc tct ctg gtg tac cag aac aat ctt aaa caa tga cga cga cca taa tgG GTA CCA TAC CT
            710          720           730          740          750           760          770          780           790 
                                                                     T7 terminator                   3'final primer       
                                                                     |                               |
T GAA TTG TAC AAA TAA TAA CGA CTC AGG CTG CTA CCT AGC ATA ACC CCT TGG GGC CTC TAA ACG GGT CTT GAG GGG TTT TTT G <883
  E   L   Y   K   *   *  
A CTT AAC ATG TTT ATT ATT GCT GAG TCC GAC GAT GGA TCG TAT TGG GGA ACC CCG GAG ATT TGC CCA GAA CTC CCC AAA AAA C 
             810          820          830          840           850          860          870           880 
Features :
enhancedGFP      : [100 : 816]
5'final primer   : [1 : 19]
T7 promoter      : [20 : 42]
RBS              : [86 : 92]
T7 terminator    : [836 : 865]
3'final primer   : [866 : 883]
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Table 2.5.1: Oligomer sequences for assembly of yEGFP linear expression construct 
Oligomer name (length) Sequence (5’ to 3’) 
biotin-3’final (initiator oligomer; 18 nt) biotin-CAAAAAACCCCTCAAGAC  
EGFP-ExtOligo1 (90 nt) GTATGGATGAATTGTACAAATAATAACGACTCAGGCTGCTACCTAGCATAA… 
        CCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTG 
EGFP-ExtOligo2 (90 nt) tccaaacgaaaagagagaccacatggtcttgttagaatttgttactgctgct… 
        ggtattacCCATGGTATGGATGAATTGTACAAATAATA 
EGFP-ExtOligo3 (90 nt) ggtgatggtccagtcttgttaccagacaaccattacttatccactcaatctg… 
        ccttatccaaagatccaaacgaaaagagagaccacatg 
EGFP-ExtOligo4 (90 nt) ttagacacaacattgaagatggttctgttcaattagctgaccattatcaacaa… 
        aatactccaattggtgatggtccagtcttgttaccag 
EGFP-ExtOligo5 (90 nt) taactctcacaatgtttacatcatggctgacaaacaaaagaatggtatcaaagt… 
        taacttcaaaattagacacaacattgaagatggttc 
EGFP-ExtOligo6 (90 nt) gaattaaaaggtattgattttaaagaagatggtaacattttaggtcacaaattg… 
        gaatacaactataactctcacaatgtttacatcatg 
EGFP-ExtOligo7 (90 nt) atgacggtaactacaagaccagagctgaagtcaagtttgaaggtgataccttag… 
        ttaatagaatcgaattaaaaggtattgattttaaag 
EGFP-ExtOligo8 (90 nt) acatgactttttcaagtctgccatgccagaaggttatgttcaagaaagaactatt… 
        tttttcaaagatgacggtaactacaagaccagagc 
EGFP-ExtOligo9 (90 nt) accttagtcactactttaacttatggtgttcaatgtttttctagatacccagatc… 
        atatgaaacaacatgactttttcaagtctgccatg 
EGFP-ExtOligo10 (90 nt) ctacttacggtaaattgaccttaaaatttatttgtactactggtaaattgccagt… 
        tccatggccaaccttagtcactactttaacttatg 
EGFP-ExtOligo11 (90 nt) ggttgaattagatggtgatgttaatggtcacaaattttctgtctccggtgaaggt… 
        gaaggtgatgctacttacggtaaattgaccttaaa 
EGFP-ExtOligo12 (90 nt) cttaagaaggaggaaaaaaaaatgtctaaaggtgaagaattattcactggtgttg… 
        tcccaattttggttgaattagatggtgatgttaat 
EGFP-ExtOligo13 (102 nt) gatcttaaggctagagtacTAATACGACTCACTATAGGGAGACCACAACGGTTTC… 
          CCTCTAGAAATAATTTTGTTTAACttaagaaggaggaaaaaaaaatg 
3’final check (18 nt) CAAAAAACCCCTCAAGAC  
Step1 check (20 nt) GTATGGATGAATTGTACAAA 
Step2 check (18 nt) tccaaacgaaaagagaga 
Step3 check (21 nt) ggtgatggtccagtcttgtta 
Step4 check (20 nt) ttagacacaacattgaagat 
Step5 check (25 nt) taactctcacaatgtttacatcatg 
Step6 check (23 nt) gaattaaaaggtattgattttaa 
Step7 check (22 nt) atgacggtaactacaagaccag 
Step8 check (20 nt) acatgactttttcaagtctg 
Step9 check (25 nt) accttagtcactactttaacttatg 
Step10 check (19 nt) ctacttacggtaaattgac 
Step11 check (25 nt) ggttgaattagatggtgatgttaat 
Step12 check (20 nt) cttaagaaggaggaaaaaaa 
Step13 check/5’final (19 nt) gatcttaaggctagagtac 
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Table 2.5.2: APE ZFA assembly oligomer sequences  
Oligomer Name Sequence (5’ to 3’)   
Oligo1Finger3 (O1F3) 
74 nt 
ttgcgacatctgcggtcgtaaattcgctXXXXXXXXXXXXXXXXXXXXXcacaccaaaatccacctgcgtcaga   
Oligo2Linker3-2 
(O2link3-2), 60 nt 
cacatccgtacccacaccggtgaaaaaccgttcgcttgcgacatctgcggtcgtaaattc 
 
  
Oligo3Finger2 (O3F2) 
77 nt 
CCAatgtagaatttgtatgagaaatttctctXXXXXXXXXXXXXXXXXXXXXcacatccgtacccacaccggtgaaa   
Oligo4Linker2-1 
(O4link2-1), 60 nt 
catattagaattcatactggacaaaAACCATTCCAatgtagaatttgtatgagaaatttc 
 
  
Oligo5Finger1 (O5F1) 
71 nt 
tgaatcttgcgaccgtcgtttctctXXXXXXXXXXXXXXXXXXXXXcatattagaattcatactggacaaa   
Biotinylated initiator 
oligo, 25 nt 
biotin-tctgacgcaggtggattttggtgtg   
Assembly check3-f 
(5’chk3-finger1) 
tgaatcttgcgaccgtcgtttctct   
Assembly check2-f 
(5’chk2-finger2) 
catattagaattcatactggacaaaaaccattcc 
 
  
Assembly check1-f 
(5’chk1-finger3) 
cacatccgtacccacaccggtg 
 
  
Assembly check-r 
(zif268-3’chk) 
tctgacgcaggtggattttggtg   
Where xxxxx indicates location of 21 nt coding for 7 amino acids in positions -1 to 6 of recognition helix.  
Oligomers 1-5 are used for modular construction of ZFAs.  The Assembly check primers were used in initial 
tests to verify the success of oligomer extension after various rounds of APE assembly.  For PCR 
amplification of full length product after the 5-step assembly, only Assembly check3-f and check-r are 
needed. 
 
 
Table 2.5.3 : APE assembly oligomers for Zif268, 37-12, 92-1, 158-2  
Oligomer Name Sequence (5’ to 3’) 
Zif268_Oligo1fin3 ttgcgacatctgcggtcgtaaattcgctcgttctgacgaacgtaaacgtcacaccaaaatccacctgcgtcaga 
Zif268_Oligo3fin2 CCAatgtagaatttgtatgagaaatttctctcgttctgaccacctgaccacccacatccgtacccacaccggtgaaa 
Zif268_Oligo5fin1 tgaatcttgcgaccgtcgtttctctcgttctgacgaactgacccgtcatattagaattcatactggacaaa 
37-12Oligo1fin3 ttgcgacatctgcggtcgtaaattcgctCGTCACGACCAGCTGACCCGTcacaccaaaatccacctgcgtcaga 
37-12Oligo3fin2 CCAatgtagaatttgtatgagaaatttctctGACCGTGCTAACCTGCGTCGTcacatccgtacccacaccggtgaaa 
37-12Oligo5fin1 tgaatcttgcgaccgtcgtttctctCGTAACTTCATCCTGCAGCGTcatattagaattcatactggacaaa 
92-1Oligo1fin3 ttgcgacatctgcggtcgtaaattcgctGAACGTGGTAACCTGACCCGTcacaccaaaatccacctgcgtcaga 
92-1Oligo3fin2 CCAatgtagaatttgtatgagaaatttctctCAGCGTTCTTCTCTGGTTCGTcacatccgtacccacaccggtgaaa 
92-1Oligo5fin1 tgaatcttgcgaccgtcgtttctctGACTCTCCGACCCTGCGTCGTcatattagaattcatactggacaaa 
158-2Oligo1fin3 ttgcgacatctgcggtcgtaaattcgctCAGTCTACCTCTCTGCAGCGTcacaccaaaatccacctgcgtcaga 
158-2Oligo3fin2 CCAatgtagaatttgtatgagaaatttctctGTTCGTCACAACCTGACCCGTcacatccgtacccacaccggtgaaa 
158-2Oligo5fin1 tgaatcttgcgaccgtcgtttctctGACAAAACCAAACTGCGTGTTcatattagaattcatactggacaaa 
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Table 2.5.4 : Gene synthesis technique error rate comparison (for Figure 2.2.8) 
year Previously reported error rates (publication reference) Assembly 
technique 
Before 
2004 PA Carr et al, Protein mediated error correction for de novo DNA synth, NAR 
2004 
PCR assembly 1.8 error/kb 
2004 Xiong A-S et al, A simple, rapid, high fidelity and cost-effective PCR-based 
2step DNA synthesis method for long gene sequences, NAR 2004 
PCR assembly 
PTDS 
0.84-6.72 error/kb 
2005 Binkowski BF et al, Correcting errors in synthetic DNA through consensus 
shuffling, NAR 2005 
PCR assembly 0.98-1.3 errors/kb 
2005 Fuhrmann M et al, Removal of mismatched bases from synthetic genes by 
enzymatic mismatch cleavage, NAR 2005 
ligation 5.8-7.2 error/kb 
2006 Xiong A-S et al, PCR-based accurate synthesis of long DNA sequences, 
NatureProtocols 2006 
PCR assembly <1 error/kb 
2007 Kong DS et al, Parallel gene synthesis in a microfluidic device, NAR 2007 PCR 1.8-2.2 error/kb 
2007 Mamedov TG et al, Rational denovo gene synth by rapid PCA and 
expression of endothelial protein-c and thrombin receptor genes, J 
Biotechnol 2007 
PCR, PCA, 
fastPCA 
0.53-1.1 error/kb 
2008 Marsic D et al, PCR-based gene synthesis to produce recombinant proteins 
for crystallization, BMC Biotech 2008 
SeqTBIO 1-3 error/kb 
2009 Ye H et al, Experimental analysis of gene assembly with TopDown one-step 
real-time gene synth, NAR 2009 
PCA assembly no consideration of error rate 
2010 Matzas M et al, High-fidelity gene synthesis by retrieval of sequence-verified 
DNA identified using HT pyrosequencing, Nature Biotech 2010 
PCR assembly 25 error/kb (starting oligomers) 
2010 Kosuri S et al, Scalable gene synth by selective amplification of DNA pools 
from highfidelity microchips, Nat Biotech 2010 
PCR assembly 0.67-0.88 errors/kb 
2010 Borovkov AY et al, High-quality gene assembly directly from unpurified 
mixtures of microarray-synthesized oligos, NAR 2010 
Ligation, 
Overlapping 
PCR 
2.7-2.9 errors/kb 
2011 Quan J et al, Parallel onchip gene synth and application to optimization of 
protein expression, Nat Biotech 2011 
PCA 1.9 error/kb 
2012 Saaem I et al, Error correction of microchip synthesized genes using 
Surveyor nuclease, NAR 2012 
nSDA-PCA, 
PCR 
1.9 error/kb 
2012 Schwartz JJ et al, Accurate gene snthesis with tag-directed retrieval of 
sequence-verified DNA molecules, Nat Methods, 2012 
Dialout PCR   
2012 Ma S et al, Error Correction in gene synthesis technology, Trends 
Biotechnol, 2012 
various   
2013 Dormitzer PR et al, Synthetic generation of influenza vaccine viruses for 
rapid response to pandemics, Science translation med, 2013 
Ligation+PCA 0.64-0.75errors/kb 
2014 Wan W et al, Error removal in microchip-synthesized DNA using immobilized 
MutS, NAR 2014 
PCR 11.44-14.25/kb 
2014 Currin A, et al, SpeedyGenes: an imporoved gene syntehsis method for 
efficient production of error-corrected, synthetic protein libraries for directed 
evolution, Protein Engineering, Design & Selection 2014 
PCR functional colony output, no seq 
data 
2015 APE solid phase gene synthesis  APE 0.78error/kb (with Phusion 
polymerase) 
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Figure 2.5.2 : Complete annotated DNA sequence of expression-ready linear template for WT Zif268.  To 
create ZF variants, substitute in the coding sequence (21 nt, in blue) for residues -1 to 6 of recognition helix 
into the positions of finger 1, 2 and 3. 
 
 
 
gat ctt aag gct aga gta cTA ATA CGA CTC ACT ATA GGG AGA CCA CAA CGG TTT CCC TCT AGA AAT AAT T  <70 
            10           20           30            40           50           60  
 
TT GTT TAA Ctt aag aag gag gaa aaa aaa atg gaa cgt ccg tac gct tgc ccg gtt gaa tct tgc gac cg  <140 
                                       M   E   R   P   Y   A   C   P   V   E   S   C   D   R  
            80           90            100          110          120           130  
 
              finger1         
t cgt ttc tct cgt tct gac gaa ctg acc cgt cat att aga att cat act gga caa aAA CCA TTC CAa tgt  <210 
  R   F   S   R   S   D   E   L   T   R   H   I   R   I   H   T   G   Q   K   P   F   Q   C    
             150          160          170          180           190          200  
 
                                finger2         
aga att tgt atg aga aat ttc tct cgt tct gac cac ctg acc acc cac atc cgt acc cac acc ggt gaa a  <280 
R   I   C   M   R   N   F   S   R   S   D   H   L   T   T   H   I   R   T   H   T   G   E   K 
            220          230          240           250          260          270  
 
                                                   finger3         
aa ccg ttc gct tgc gac atc tgc ggt cgt aaa ttc gct cgt tct gac gaa cgt aaa cgt cac acc aaa at  <350 
   P   F   A   C   D   I   C   G   R   K   F   A   R   S   D   E   R   K   R   H   T   K   I  
            290          300           310          320          330           340  
                             
c cac ctg cgt cag aaa gac cca gcg cca gcg cca tct aaa ggt gaa gaa tta ttc act ggt gtt gtc cca  <420 
  H   L   R   Q   K   D   P   A   P   A   P   S   K   G   E   E   L   F   T   G   V   V   P    
             360          370          380          390           400          410  
    
att ttg gtt gaa tta gat ggt gat gtt aat ggt cac aaa ttt tct gtc tcc ggt gaa ggt gaa ggt gat g  <490 
I   L   V   E   L   D   G   D   V   N   G   H   K   F   S   V   S   G   E   G   E   G   D   A 
            430          440          450           460          470          480  
    
ct act tac ggt aaa ttg acc tta aaa ttt att tgt act act ggt aaa ttg cca gtt cca tgg cca acc tt  <560 
   T   Y   G   K   L   T   L   K   F   I   C   T   T   G   K   L   P   V   P   W   P   T   L  
            500          510           520          530          540           550  
    
a gtc act act tta act tat ggt gtt caa tgt ttt tct aga tac cca gat cat atg aaa caa cat gac ttt  <630 
  V   T   T   L   T   Y   G   V   Q   C   F   S   R   Y   P   D   H   M   K   Q   H   D   F    
             570          580          590          600           610          620  
    
ttc aag tct gcc atg cca gaa ggt tat gtt caa gaa aga act att ttt ttc aaa gat gac ggt aac tac a  <700 
F   K   S   A   M   P   E   G   Y   V   Q   E   R   T   I   F   F   K   D   D   G   N   Y   K 
            640          650          660           670          680          690  
                                                       
ag acc aga gct gaa gtc aag ttt gaa ggt gat acc tta gtt aat aga atc gaa tta aaa ggt att gat tt  <770 
   T   R   A   E   V   K   F   E   G   D   T   L   V   N   R   I   E   L   K   G   I   D   F  
            710          720           730          740          750           760  
    
t aaa gaa gat ggt aac att tta ggt cac aaa ttg gaa tac aac tat aac tct cac aat gtt tac atc atg  <840 
  K   E   D   G   N   I   L   G   H   K   L   E   Y   N   Y   N   S   H   N   V   Y   I   M    
             780          790          800          810           820          830  
    
gct gac aaa caa aag aat ggt atc aaa gtt aac ttc aaa att aga cac aac att gaa gat ggt tct gtt c  <910 
A   D   K   Q   K   N   G   I   K   V   N   F   K   I   R   H   N   I   E   D   G   S   V   Q 
            850          860          870           880          890          900  
   
aa tta gct gac cat tat caa caa aat act cca att ggt gat ggt cca gtc ttg tta cca gac aac cat ta  <980 
   L   A   D   H   Y   Q   Q   N   T   P   I   G   D   G   P   V   L   L   P   D   N   H   Y  
            920          930           940          950          960           970  
 
c tta tcc act caa tct gcc tta tcc aaa gat cca aac gaa aag aga gac cac atg gtc ttg tta gaa ttt  <1050 
  L   S   T   Q   S   A   L   S   K   D   P   N   E   K   R   D   H   M   V   L   L   E   F    
             990          1000         1010         1020          1030         1040  
                                                                       
gtt act gct gct ggt att acC CAT GGT ATG GAT GAA TTG TAC AAA ggg ggt tct cat cat cat cat cat c  <1120 
V   T   A   A   G   I   T   H   G   M   D   E   L   Y   K   G   G   S   H   H   H   H   H   H 
            1060         1070         1080          1090         1100         1110  
 
at TAA TAA CGA CTC AGG CTG CTA CCT AGC ATA ACC CCT TGG GGC CTC TAA ACG GGT CTT GAG GGG TTT TTT GA  
   *   *    1130         1140          1150         1160         1170          1180  
Features : 
T7 promoter: [19 : 42], RBS: [86 : 92] 
finger1: [151 : 171], finger2: [235 : 255], finger3: [319 : 339] 
proline linker: [365 : 384], yEGFP: [385 : 1095], 6x Histidine tag: [1105 : 1122], T7 terminator: [1145 : 1192] 
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Table 2.5.5 : Oligomers for generation of linear expression template with GFP fusion 
Oligomer Name Sequence (5’ to 3’) 
yEmCitrine-R1-f CCTCTAGAAATAATTTTGTTTAACTTAAGAAGGAGGAAAAAAAAatgtctaaaggtgaagaattattcac 
yEmCitrine-r GTAGCAGCCTGAGTCGTTATTATTTGTACAATTCATCCATACCATGG 
Proline-linker-EGFP-f cacaccaaaatccacctgcgtcagaaagacccagcgccagcgccatctaaaggtgaagaattattcac 
EGFP-His6-r GTAGCAGCCTGAGTCGTTATTAatgatgatgatgatgatgagaacccccTTTGTACAATTCATCCATACCATGG 
Genespecific-f AGAAATAATTTTGTTTAACttaagaaggaggaaaaaaaaatggaacgtccgtacgcttgcccggttgaatcttgcgaccgtcgtttctct 
Extension-f gatcttaaggctagagtacTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTA
ACttaagaagga 
Extension-r CAAAAAACCCCTCAAGACCCGTTTAGAGGCCCCAAGGGGTTATGCTAGGTAGCAGCCTGAGTCG 
5’final_highTm Cy3-gatcttaaggctagagtacTAATACGACTCACTATAGGG 
3’final_highTm CAAAAAACCCCTCAAGACCCGTTTAGAG 
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Figure 2.5.3 : Time estimates for performing up to 12 unique (no reaction pooling and splitting) APE 
assembly reactions by hand.  Following the assembly reaction, several PCRs are performed to confirm full-
length assembly, and to add on sequence necessary for on-chip expression and detection (5’ and 3’UTRs, 
EGFP tag).  Representative gels for the assembly of 5 templates during each step are shown.  Finally, 
another list of time estimates for the microarraying process and running MITOMI experiments is given. 
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Chapter 3:  
C2H2 ZF Modular Combinatorics 
 
 
3.1 Introduction 
 
 Following the development of APE assembly for ZFA variants, we were interested 
in validating the versatility and speed of the platform by creating a library of ZFAs from the 
oligomer parts we already had available.  Optimization of the APE assembly technique 
was performed with 4 ZFA variants: WT Zif268 and three synthetic proteins 37-12, 92-1 
and 158-2 from (156).  The amino acid residues of the recognition helices and the DNA 
target triplets for each ZF domain are given below in Figure 3.1.1. 
 
Figure 3.1.1 : The four ZFAs and their amino acid residues for determining target specificity are listed.  Each 
finger has a specific DNA target sequence.  The residues are reversed in the lower box to indicate the 
location of the residues when they bind to DNA. 
 
Zif268 (wt) finger 1 finger 2 finger 3
RSDELTR RSDHLTT RSDERKR
C RKREDSR TTLHDSR RTLEDSR N
5'- a GCG      TGG     GCG t
6 5 4 3 2 1 -1 6 5 4 3 2 1 -1 6 5 4 3 2 1 -1
37-12 finger 1 finger 2 finger 3
RNFILQR DRANLRR RHDQLTR
C RTLQDHR RRLNARD RQLIFNR N
5'- t GAG     GAC     GTG t
6 5 4 3 2 1 -1 6 5 4 3 2 1 -1 6 5 4 3 2 1 -1
92-1 finger 1 finger 2 finger 3
DSPTLRR QRSSLVR ERGNLTR
C RTLNGRE RVLSSRQ RRLTPSD N
5'- a GAT      GTA     GCC t
6 5 4 3 2 1 -1 6 5 4 3 2 1 -1 6 5 4 3 2 1 -1
158-2 finger 1 finger 2 finger 3
DKTKLRV VRHNLTR QSTSLQR
C RQLSTSQ RTLNHRV VRLKTKD N
5'- t GTA      GAT      GGA g
6 5 4 3 2 1 -1 6 5 4 3 2 1 -1 6 5 4 3 2 1 -1
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In early MITOMI experiments, we demonstrated that each of these ZFAs were functional 
(capable of binding their consensus target), but we had not characterized their specificity 
beyond the original set of four DNA targets.  Each ZFA assembly required 3 unique ‘finger’ 
oligomers in addition to the 2 universal ‘linking’ oligomers, as explained in Chapter 2.  The 
finger oligomers were designed such that only the central part of each oligomer uniquely 
encoded the recognition helix variants (residues -1 to 6).  The flanking sequence at the 
termini of each finger oligomer remained constant, meaning all oligomers designed for a 
particular finger position could be interchanged.  This meant that we could generate up to 
64 ZFAs simply by shuffling the 12 finger oligomers that encoded the original set of 4 
ZFAs.   
APE assembly was applied towards the generation of the 64 ZFAs, and each 
assembly product was PCR amplified and extended to prepare EGFP-fusion, expression-
ready linear templates (see Methods 2.4 for APE assembly and PCR steps).  To provide a 
simple pattern for naming the 64 variants, each of the original ZFAs were labeled A 
through D (Zif268 = A, 37-12 = B, 92-1 = C, 158-2 = D).  Variants made by combining ZF 
domains from these different ZFAs were named from C to N-terminus (in the direction of 
target binding).  For example, a variant with Finger1 from 37-12, Finger2 from 92-1, and 
Finger3 from Zif268 would be named ACB (from C- to N-terminus).  To characterize the 
binding affinity and specificity of each of these variants, a panel of target sequences were 
synthesized, where the expected target consensus for each variant was simply the 
concatenation of each finger’s cognate DNA triplet.  Targets were labeled in a similar 
fashion, from 5’ to 3’, such that the target had the same name as the protein expected to 
bind it (ie, protein ACB has the expected consensus target ACB).  Each ZFA variant was 
tested in combination with the full panel of DNA targets to evaluate their specificity using a 
1024 unit MITOMI microfluidic device.  Details of device preparation and operation, in 
addition to fluorescent image analysis and affinity calculation are given in the Methods 
section 3.4. 
 
 
3.2 Results 
 
We synthesized 64 different ZFAs and quantified binding of each against a library of 
the corresponding 64 predicted consensus DNA targets.  APE-MITOMI successfully 
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expressed all 64 ZFs (EGFP signal and levels of target DNA binding were observed for all 
variants).  The filled line plot in Figure 3.2.1 was made by rank-ordering all of the ZFA 
variants by order of their highest observed binding affinity.  A solid black line indicates the 
arbitrary cut-off for ZFAs considered ‘non-functional’.  These six ZFAs bound to targets 
very weakly relative to the others, and they were deemed non-functional because their 
expected consensus target was not found within the top 10 highest bound targets.  As 
displayed in pie charts of Figure 3.2.1, 90.6% (58/64) of the ZFA variants bound DNA.  Of 
those ZFs that bound DNA, 89.7% (52/58) bound the expected consensus target within the 
top 4 highest-affinity targets and 58.6% (34/58) bound the expected target with highest 
affinity.  
 
 
 
Figure 3.2.1 : Overview of experimental results obtained from combinatoric assembly of ZFAs demonstrating 
protein expression and functional DNA binding success rates.   
???????
??
??
??
???
??
??
??
???
??
??
???
??
??
??
????????????????????????????????????????????????????
??
??
??
??
??????????????
??????????????????
??????? ????
??????????????
???????????????
?????????
?????
??????
?????
?????????????
?????
??????
???????
????
??
? 68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.2 : Heatmap of dimensionless, relative binding affinities for each assembled ZFA variant (y-axis) 
to 64 predicted consensus DNA targets (x-axis).  The protein naming convention indicates ZF domains from 
C-to-N (F3 to F1), where AAA (Af3Af2Af1)=Zif268, BBB=37-12, CCC=92-1, DDD=158-2 (156); for example, 
protein ABC = F3 from zif268, F2 from 37-12, F1 from 92-1; target ABC = Zif268 F3 binding consensus triplet 
GCG, 37-12 F2 binding consensus GAC, 92-1 F1 binding consensus triplet GCC (5’-GCG GAC GCC).  
Oligomer assembly and target sequences are given in Supplementary Tables 3.5.1 and 2. 
 
To verify that failure to bind and that sequence specificity was unaffected by our approach, 
we cloned and sequence verified the CCC and DDD ZFA variants generating the plasmid-
based versions CCCp and DDDp (see Figure 3.2.2).  Both plasmid-based ZFAs gave 
identical results when compared to non-sequenced versions.  Due to the low APE 
assembly error-rate as well as the on-chip purification of only properly folded ZFA-EGFP 
fusions, all future experiments were performed without sequence verification of constructs.  
The heat map shows the quantitative binding specificity of each of the 64+2 ZFA variants.  
Except for 6 ZFA-DNA pairs out of 4096 potential combinations, all of the affinity data in 
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Figure 3.2.2 are the average of a least 2 datapoints from different experiments.  On 
average, each interaction was evaluated 5 times in different MITOMI experiments.  The 
heatmap displays the average affinity values obtained from over 24,000 data points. 
  
 
3.3 Discussion 
 
This approach of rapidly generating ZFAs and evaluating their target specificities 
can be used to identify orthogonal ZFAs for use in the design and implementation of 
synthetic genetic networks (156) and to eliminate ZFAs with sub-optimal binding 
characteristics such as low affinity or extensive non-specific binding.  As seen in Figure 
3.2.2, we observed that ZFAs containing a ‘C’ finger in position F2 exhibited high levels of 
non-specific binding, especially when combined with finger variants A and B in position F3 
(see Figure 3.2.2).   
Due to the cross-strand interaction of residue 2 in the recognition helix, and 
variations in the types of assays used to evaluate DNA specificity, the modularity of ZFAs 
has been repeatedly questioned (117, 271).  Studies evaluating ZF nuclease cleavage 
frequently reported high failure rates for their modularly derived variants.  ZF nuclease 
cleavage relies on the dimerization of two FokI nuclease domains brought into proximity by 
fusing them to site-specific ZFAs that target regions on either side of the desired cut site 
(144).  DNA cleavage failure is a difficult situation to troubleshoot due to the number of 
variables that can lead to failure: non-specific or low-affinity binding of the ZFAs, 
inadequate linker length for fusion to the FokI domain, insufficient amounts of the proteins 
to cause cleavage, and complications with the reporter used to quantify cleaving efficiency.  
By assaying ZFAs purely on their ability to bind DNA, it is commonly seen that ZFAs 
constructed by modular combinations of characterized domains were functional (117, 272, 
273).  The modular combination results we present here corroborate with results observed 
in other in vivo and in vitro studies. 
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3.4 Methods 
 
3.4.1 dsDNA Target Synthesis  
 
Double stranded DNA targets (dsDNA) for zinc-finger array binding were prepared 
via isothermal Klenow extension as previously described (210).  Oligomers were designed 
such that the DNA contains the 9 nt target sequence with single nucleotide flanks (11 nt 
total). At the 3’end of the DNA is the complementary sequence for a Cy5-labeled primer 
(5’CompCy5; Table 3.4.1).  The reaction consists of 2 steps, one annealing step, and one 
extension step.  Each 20 μL annealing reaction contains 1x NEB Buffer 2, 10 μM 
5’CompCy5, and 15 μM Target oligomer.  This mixture was placed on a thermocycler, 
heated to 94°C for 5 minutes, then cooled to 37°C (10% ramp) for 5 minutes, then held at 
20°C.  Following the annealing program, 10 μL of extension mix (1x NEB Buffer 2, 3mM 
dNTPs, and 2.5 units Klenow exo-) are spiked into the annealing mix, and the reaction is 
thermocycled according to the following routine: 37°C, 90min; 75°C heat kill, 20min; 10% 
ramp down to 30°C, 30s; hold at 4°C. 
 
Table 3.4.1 : Klenow extension, Cy5-labelled target oligomer design 
Oligomer Name Sequence (5’ to 3’) 
5’CompCy5 Cy5-GTCATACCGCCGGA 
Target design GGCCAATT X XXX XXX XXX X TTTCCGGCGGTATGAC 
Where xxxx indicates location of target sequence (11 nt target = 9 nt binding site with flanking nt on each 
end)  
 
3.4.2 Microarray printing 
 
Preparation of epoxy-silane glass slides 
 
For microarray printing, epoxy-silane functionalized glass slides were prepared, 
following an adapted protocol (274).  A MilliQ water and ammonia solution (NH4OH, 25%) 
mixture was prepared in a 5:1 ratio, respectively, and heated to 80°C.  Then, 150 mL of 
hydrogen peroxide (H2O2, 30%) was added to the mixture, and glass microscope slides 
were placed in the cleaning bath for 30 minutes.  The glass slides were then removed and 
rinsed in fresh MilliQ water, dried with N2, and placed in a second bath containing 1% 3-
glycidoxypropyltrimethoxymethylsilane (97% purity) in toluene, and incubated for at least 
20 minutes at ambient temperature.  Then, the glass slides were removed, rinsed in fresh 
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toluene, dried with N2, and baked at 80°C for 30 minutes.  The glass slides were removed 
from the oven, allowed to cool, and stored under vacuum at room temperature in opaque 
storage boxes until used.  Immediately prior to microarray printing, both sides of each 
glass slide is briefly rinsed with fresh isopropanol, dried with N2, rinsed with fresh toluene, 
and dried with N2 again.      
 
Sample microarraying 
 
All samples to be printed onto a microarray were prepared in a 384-well microtiter 
plate.  Each zinc-finger array assembly (1192 bp PCR product) was co-spotted with a 
target DNA (Klenow extended products) in duplicate onto epoxy-silane coated glass slides 
using a microarray robot (QArray2) with a 946MP4 microspotting pin (Arrayit).  Up to four 
slides were prepared in a single printing session.  Each spot on the array was generated 
by four consecutive printing programs.  Immediately following completion of printing from a 
given sample plate, the sample wells were covered with adhesive PCR foil seals 
(ThermoScientific) and stored at -20°C until needed for future printing runs.  In general, 
Klenow target plates were re-used for up to 5 printing runs before the volume of each well 
became too low to be used.  After the final printing program, the microspotting pin is 
cleaned by sonication for 15min in a 15 mL Falcon tube containing one drop of dish 
detergent and 10 mL of deionized water, then sonicated for 30min in a 15 mL Falcon tube 
containing 10 mL of 70% ethanol in water.  Before use, the pin tip is rinsed under 
deionized water, dried using a high pressure (100 psi) compressed air gun, then inspected 
under a microscope to verify the tip is clean and free of debris.  Finally, the shaft of the pin 
is briefly polished with a dry Kimwipe to prevent sticking when placed into the robotic 
printer head. 
 
Microarray Printing Routine 
 
The first BSA printing routine is to block the surface of the glass, to limit the amount 
of template and target DNA that is irreversibly attached to the epoxy-silane surface.  The 
second BSA printing routine is implemented to deposit a thin blocking layer on top of the 
printed template spots, to reduce the risk of cross-contamination due to template carry-
over during target printing (since target printing does not involve same-sample washing 
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steps).  The full printing routine and operational details can be found in Table 3.4.2 and 
Figure 2.5.3.   
 
Table 3.4.2 : Microarray robotic printing routine 
Step Printing reagent Stamps
/spot 
Stamps
/ink 
Humidity Wash frequency 
1 
(prespot) 
0.5% BSA in water 1  4 45-55% No same-sample wash, 1 
source well per linear template 
2 Linear template printing (6 
μL final PCR product + 64 
μL 2% BSA in water)  
2 4 45-55% Wash after 32 inks 
3 
(overspot) 
0.5% BSA in water 1 4 45-55% No same-sample wash, 1 
source well per linear template 
4 Cy5-DNA target printing 
(10 μL Klenow product + 
60 μL 2% BSA in water)  
3 3 45-55% Wash after 32 inks 
 
 
3.4.3 MITOMI chip fabrication and operation 
 
Mold Fabrication 
 
The MITOMI microfluidic device (204, 275) (Figure 1.4.1-3) consists of two 
superimposed layers, the flow layer and the control layer.  Each layer is fabricated in 
polydimethylsiloxane (PDMS) using 4” silicon wafer molds fabricated using standard 
lithography techniques(206).  Each wafer (control and flow) contained three pattern 
replicates for a 1024-chamber (16 rows by 64 columns) MITOMI device. 
Mask fabrication was carried out using a Heidelberg DWL200 laser lithography 
system with 10mm writing head and solid state wavelength stabilized laser diode (max. 
110 mW at 405 nm).  Each layer of the MITOMI device was reproduced as a chrome 
mask.  After laser writing, the chrome mask is cycled twice for 15s in developer mixture 
(1:5 MP351 and deionized water, respectively), 45s of agitation, then rinsed and dried.  
The developed mask is then chrome etched for 110s, rinsed, cleaned twice for 15min in 
1165-remover bath, rinsed and air dried.    
The flow layer mold is first cleaned for 7 min in a Tepla300 plasma stripper with 400 
mL/min O2 at 500W and 2.45 GHz.  The wafer is then treated with hexamethyldisilazane 
(HMDS) using an ATMsse hotplate at 125°C for 12min.  Positive photoresist AZ9260 is 
spin-coated on the cleaned wafer for 10s at 800 rpm, then 40s at 1800 rpm (ramp 1000 
rpm/s) to produce a substrate height of 14 μm.  The wafer is then baked on a 115°C 
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hotplate for 6min.  The soft-baked positive resist is then allowed to rehydrate for 1h.  The 
wafer is then exposed during 3 intervals of 18s with a 10s pauses between each exposure 
on a MA6 mask aligner (power 360 mJ/cm2, intensity 10 mW/cm2, broad-spectrum lamp, 
hard contact exposure mode).  After a 1h relaxation time, the wafer is developed in a DV10 
chamber via multiple, automated cycles of rinsing/agitation with development mixture (1:4 
ratio of AZ400K and deionized water, respectively) until the features are visible.  Finally, 
the wafer is heated to 160°C for 20 minutes to anneal and round the features of the flow 
wafer to create a profile that allows complete valve closure. 
The control layer mold is first cleaned following the same plasma treatment protocol 
as the flow layer mold.  Negative photoresist SU-8 GM1060 (Gestertec) is spin-coated on 
the cleaned wafer for 10s at 500 rpm (ramp 100 rpm/s), 10s at 1500 rpm (ramp 100 
rpm/s), 1s at 2500 rpm, and finally 6s at 1500 rpm to produce a substrate height of 14 μm.  
The wafer is baked on a hotplate for 30min at 130°C, then 25min at 30°C.  The wafer is 
then exposed on a MA6 mask aligner for 13.2s (power 360 mJ/cm2, intensity 10mW/cm2, 
broad-spectrum lamp, hard contact exposure mode).  The exposed wafer is developed 
manually by bathing in PGMEA twice for 1.5min, then rinsed in isopropanol and dried with 
an air gun.   
 
Device Fabrication 
 
Prior to PDMS casting, both the flow and control layer wafers are subjected to vapor 
deposition of trimethylchlorosilane (TMCS, EMD Millipore Corp.) for at least 30min by 
placing them within a sealed plastic container with a small dish containing 0.25 mL liquid 
TMCS. TMCS treatment is repeated for at least 15min before all subsequent PDMS 
casting rounds.  The control layer wafer is placed into an aluminum foil-lined glass Petri 
dish, and 60g of Sylgard elastomer  (5:1 mix of elastomer base and curing agent, 
respectively) is mixed for 1min at 2000rpm (400×g) and degassed for 2min at 2200 rpm 
(440×g) in a centrifugal mixer.  The elastomer mixture is poured on top of the control layer 
in the Petri dish, and degassed in a vacuum dessicator for 20min at ambient temperature.   
For the flow layer, 21 g of PDMS mixture is prepared at the ratio of 20:1 
(base:curing agent), then mixed and degassed in a centrifugal mixer according to the 
same speeds and times as the control layer.  The flow wafer is carefully centered on top of 
a spin-coater platform using wafer tweezers, and the flow layer PDMS mixture is poured in 
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the center, taking care not to create any bubbles.  The mixture is spin-coated onto the 
wafer with a 15s ramp and 35s spin at 2800 rpm. The degassed PDMS on the control 
layer wafer is removed from the vacuum chamber.  Residual bubbles are removed with a 
scalpel and any pieces of dust are carefully removed from the control channel grid using 
the tip of the scalpel blade.   
Both the control and flow layers are then placed into an oven at 80°C for 28-30min. 
After baking, both Petri dishes are removed from the oven and briefly allowed to cool.  The 
control layer is then cut with a scalpel in a rectangle around each pattern replicate, and 
each rectangle of cured PDMS is carefully peeled away from the silicon wafer.  Holes are 
punched through each of the control line input channels on the patterned side of the PDMS 
block.  The patterned side of the control layer is cleaned twice with Scotch Magic Tape to 
remove dust and debris then quickly placed on top of the flow layer replicates.  A 
stereomicroscope is used to precisely align the features of the control layer so that they 
overlap with the chambers visible on the flow layer.  Once aligned, the assembled device 
is bonded at 80°C for 90-180min.  The bonded devices are removed from the oven and 
briefly allowed to cool.  A scalpel is guided around the outer edge of the control layer 
PDMS block to cut the thin flow layer.  Then each individual device is gently peeled from 
the flow layer wafer, and holes are punched through the patterned side inlets and outlet of 
the flow layer.  Each device is then cleaned with Magic Scotch tape and trimmed to fit 
within the boundary defined by the glass slide-holding cartridge of the microarray scanner.  
The assembled device is aligned with a printed microarray on an epoxy-silane glass slide 
using a stereomicroscope and bonded overnight at 80°C before use. 
The flow layer mold is cleaned of residual polymerized PDMS by pouring on another 
layer of mixed PDMS (this can be leftover control- or flow-layer PDMS mixtures prepared 
earlier; to stall cross-linking for several hours, store the PDMS mixture at 4°C), and baked 
at 80°C for at least 1 hour.  The resulting thicker layer of PDMS can be easily peeled away 
from the flow layer, resulting in a clean surface to repeat the process.  Both the cleaned 
flow wafer and control wafer are cleaned with high pressure (100 psi) compressed air gun 
to dislodge pieces of dust or PDMS before being treated with TMCS. 
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Device Setup 
 
Assembled MITOMI chips bonded to microarray printed glass slides were stored at 
40°C following an overnight bonding at 80°C until used.  To begin an experiment, control 
line tubing is filled with PBS using a syringe, and pins are placed into the appropriate 
locations to feed into the control valves of the microfluidic device.  The control lines are 
actuated at low pressure (10 psi) to begin filling the control lines of the microfluidic device.  
Once all of the control lines are filled, the sandwich valves and button valves are 
deactivated, and the pressure is increased to 20-22 psi to ensure complete closure of all 
other valves.  
 
Surface Derivatization, Protein Synthesis, Binding Assay, and Device Readout 
 
Biotin-BSA (2 mg/mL) is flowed through the device for 15min at 3.5 psi.  The chip is 
then washed with 0.01% Tween20 in PBS for 5min to wash away unbound biotin-BSA.  
Next, neutravidin (1 mg/mL) is flowed for 15min followed by 0.01% Tween20 in PBS for 
5min.  The button valves are then activated and biotin-BSA is again flowed across the chip 
for 10min, blocking all of the neutravidin binding sites except those protected under the 
area of the button valve.  The chip is again washed with 0.01% Tween20 in PBS for 5min.  
Then a solution containing 0.5 μL biotinylated antibody to GFP (1 mg/mL stock, Abcam 
ab6658) in 100 μL 1% BSA in PBS is flowed across the chip for 5min, the button valve is 
deactivated, and the antibody solution is flown for 15min, allowing the antibody to bind to 
the available neutravidin under the button valve.  Then, the chip is flushed with 0.01% 
Tween20 in PBS for 5min, and with PBS for 5min.  The button valve is then activated, and 
ITT mixture (NEB PURExpress, 10 μL SolnA, 7.5 μL SolnB, 0.5 μL RNAse Inhibitor 
(Roche), 7 μL PCR grade water) is flowed for 10min. The exit valve is activated for 2min 
while the ITT is being flowed on-chip to build up pressure.  The neck valve is deactivated, 
and the ITT mixture is allowed to fill the DNA chambers for 1-2min.   
Once the DNA chambers are filled, the neck valves are activated, the exit is 
opened, and fresh ITT is allowed to flow across the chip for 10min.  Then the sandwich 
valve is activated while flowing ITT mix during the last minute of ITT washing.  Once the 
sandwich valves are partially closed, the button valve is deactivated, the neck valve is 
deactivated, the exit is closed, and the flow of ITT is stopped.  The inlet tree valve 
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controlling entry to the chamber array is closed, and the inlet tree is briefly flushed with 
0.01% Tween20 in PBS.  Then the entire chip is placed on a flatbed thermal cycler set to 
37°C, and incubated for 3-5h.  During this time, the DNA array spots are rehydrated in the 
ITT mix, transcription and translation occur, synthesized zinc-finger/EGFP fusion protein 
diffuses and is bound by the anti-GFP moiety located under the button valve, and target 
DNA diffuses and interacts with the various zinc finger DNA binding domains.  After 
incubation, the chip is placed into an ArrayWoRx microarray scanner, and an image is 
taken in three fluorescent channels (A488/GFP, Cy3, Cy5) to determine relative amounts 
of solution phase target DNA in the MITOMI chamber.  The button valves are then 
activated, the sandwich valves are deactivated, and the neck valve is activated again.  The 
flow space is washed with 0.01% Tween20 in PBS for 5min to remove unbound target 
DNA, then the chip is scanned again in the three fluorescent channels, giving the total 
protein signal (EGFP/A488 signal) and the relative amount of target bound (Cy5 signal).  
Each zinc finger fusion template was tagged with Cy3 during the final PCR step, and 
though signal from this channel was captured in each scan, it was not factored into 
downstream binding-specificity analyses, primarily because little Cy3 signal was detected 
as being bound by the ZF proteins and normalization for protein amount was performed 
with the EGFP fluorescence.   
 
3.4.4 Image Analysis and Affinity Value Calculations 
 
Images acquired from the experiment were processed using a 1024 unit detection 
array in GenePix v6.0.  Raw tif files from the ArrayWoRx scanner were loaded into the 
GenePix software, and using the grid detection tool, an array of 1024 circular areas was 
snapped onto the EGFP spots detected in the A488 channel after washing.  Small 
adjustments to the grid were performed by hand for poorly detected locations.  Mean and 
median fluorescence measurements were taken in each fluorescent channel before and 
after washing.  In addition, local background measurements were taken by dragging the 
detection array off the button valve locations into the space just outside the reaction 
chamber.  For each scan, each circular area in the array was background corrected using 
its own local background measurement.  Datapoints were filtered to ensure that EGFP 
levels were at least 500 AFU (arbitrary fluorescence units) or higher, and Cy5 target levels 
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at least 1000 AFU or higher.  These filtered, and background-corrected data points were 
used to calculate ‘relative affinity’ values (reported in AFU), using Equation 3.4.1 below: 
 
relative affinity ? ?
Cy5bound (after wash)
Cy5total (before wash)
A488??EGFP after wash? ????????????????????????????????????????????????????????????(Equation 3.4.1) 
 
These relative affinity values were used to compare ZFA binding affinity to various targets 
across different experiments.  In general, at least 2 data points were averaged together to 
arrive at a single affinity value (as in the heat map generated in Figure 3.2.2). 
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3.5 Supplementary Tables 
 
Table 3.5.1 : DNA target sequences for ZF combinatorics (Figure ) 
Oligomer Name Sequence (5’ to 3’) 
target_BAA GGC CAA TTT GAG TGG GCG TTT TCC GGC GGT ATG AC 
target_CAA GGC CAA TTA GAT TGG GCG TTT TCC GGC GGT ATG AC 
target_DAA GGC CAA TTT GTA TGG GCG TTT TCC GGC GGT ATG AC 
target_ABA GGC CAA TTA GCG GAC GCG TTT TCC GGC GGT ATG AC 
target_ACA GGC CAA TTA GCG GTA GCG TTT TCC GGC GGT ATG AC 
target_ADA GGC CAA TTA GCG GAT GCG TTT TCC GGC GGT ATG AC 
target_AAB GGC CAA TTA GCG TGG GTG TTT TCC GGC GGT ATG AC 
target_AAC GGC CAA TTA GCG TGG GCC TTT TCC GGC GGT ATG AC 
target_AAD GGC CAA TTA GCG TGG GGA GTT TCC GGC GGT ATG AC 
target_ABB GGC CAA TTA GCG GAC GTG TTT TCC GGC GGT ATG AC 
target_CBB GGC CAA TTA GAT GAC GTG TTT TCC GGC GGT ATG AC 
target_DBB GGC CAA TTT GTA GAC GTG TTT TCC GGC GGT ATG AC 
target_BAB GGC CAA TTT GAG TGG GTG TTT TCC GGC GGT ATG AC 
target_BCB GGC CAA TTT GAG GTA GTG TTT TCC GGC GGT ATG AC 
target_BDB GGC CAA TTT GAG GAT GTG TTT TCC GGC GGT ATG AC 
target_BBA GGC CAA TTT GAG GAC GCG TTT TCC GGC GGT ATG AC 
target_BBC GGC CAA TTT GAG GAC GCC TTT TCC GGC GGT ATG AC 
target_BBD GGC CAA TTT GAG GAC GGA GTT TCC GGC GGT ATG AC 
target_ACC GGC CAA TTA GCG GTA GCC TTT TCC GGC GGT ATG AC 
target_BCC GGC CAA TTT GAG GTA GCC TTT TCC GGC GGT ATG AC 
target_DCC GGC CAA TTT GTA GTA GCC TTT TCC GGC GGT ATG AC 
target_CAC GGC CAA TTA GAT TGG GCC TTT TCC GGC GGT ATG AC 
target_CBC GGC CAA TTA GAT GAC GCC TTT TCC GGC GGT ATG AC 
target_CDC GGC CAA TTA GAT GAT GCC TTT TCC GGC GGT ATG AC 
target_CCA GGC CAA TTA GAT GTA GCG TTT TCC GGC GGT ATG AC 
target_CCB GGC CAA TTA GAT GTA GTG TTT TCC GGC GGT ATG AC 
target_CCD GGC CAA TTA GAT GTA GGA GTT TCC GGC GGT ATG AC 
target_ADD GGC CAA TTA GCG GAT GGA GTT TCC GGC GGT ATG AC 
target_BDD GGC CAA TTT GAG GAT GGA GTT TCC GGC GGT ATG AC 
target_CDD GGC CAA TTA GAT GAT GGA GTT TCC GGC GGT ATG AC 
target_DAD GGC CAA TTT GTA TGG GGA GTT TCC GGC GGT ATG AC 
target_DBD GGC CAA TTT GTA GAC GGA GTT TCC GGC GGT ATG AC 
target_DCD GGC CAA TTT GTA GTA GGA GTT TCC GGC GGT ATG AC 
target_DDA GGC CAA TTT GTA GAT GCG TTT TCC GGC GGT ATG AC 
target_DDB GGC CAA TTT GTA GAT GTG TTT TCC GGC GGT ATG AC 
target_DDC GGC CAA TTT GTA GAT GCC TTT TCC GGC GGT ATG AC 
target_BCA GGC CAA TTT GAG GTA GCG TTT TCC GGC GGT ATG AC 
target_BDA GGC CAA TTT GAG GAT GCG TTT TCC GGC GGT ATG AC 
target_CBA GGC CAA TTA GAT GAC GCG TTT TCC GGC GGT ATG AC 
target_CDA GGC CAA TTA GAT GAT GCG TTT TCC GGC GGT ATG AC 
target_DBA GGC CAA TTT GTA GAC GCG TTT TCC GGC GGT ATG AC 
target_DCA GGC CAA TTT GTA GTA GCG TTT TCC GGC GGT ATG AC 
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target_ACB GGC CAA TTA GCG GTA GTG TTT TCC GGC GGT ATG AC 
target_ADB GGC CAA TTA GCG GAT GTG TTT TCC GGC GGT ATG AC 
target_CAB GGC CAA TTA GAT TGG GTG TTT TCC GGC GGT ATG AC 
target_CDB GGC CAA TTA GAT GAT GTG TTT TCC GGC GGT ATG AC 
target_DAB GGC CAA TTT GTA TGG GTG TTT TCC GGC GGT ATG AC 
target_DCB GGC CAA TTT GTA GTA GTG TTT TCC GGC GGT ATG AC 
target_ABC GGC CAA TTA GCG GAC GCC TTT TCC GGC GGT ATG AC 
target_ADC GGC CAA TTA GCG GAT GCC TTT TCC GGC GGT ATG AC 
target_BAC GGC CAA TTT GAG TGG GCC TTT TCC GGC GGT ATG AC 
target_BDC GGC CAA TTT GAG GAT GCC TTT TCC GGC GGT ATG AC 
target_DAC GGC CAA TTT GTA TGG GCC TTT TCC GGC GGT ATG AC 
target_DBC GGC CAA TTT GTA GAC GCC TTT TCC GGC GGT ATG AC 
target_ABD GGC CAA TTA GCG GAC GGA GTT TCC GGC GGT ATG AC 
target_ACD GGC CAA TTA GCG GTA GGA GTT TCC GGC GGT ATG AC 
target_BAD GGC CAA TTT GAG TGG GGA GTT TCC GGC GGT ATG AC 
target_BCD GGC CAA TTT GAG GTA GGA GTT TCC GGC GGT ATG AC 
target_CAD GGC CAA TTA GAT TGG GGA GTT TCC GGC GGT ATG AC 
target_CBD GGC CAA TTA GAT GAC GGA GTT TCC GGC GGT ATG AC 
target_268wt GGC CAA TTA GCG TGG GCG TTT TCC GGC GGT ATG AC 
target_37-12 GGC CAA TTT GAG GAC GTG TTT TCC GGC GGT ATG AC 
target_92-1 GGC CAA TTA GAT GTA GCC TTT TCC GGC GGT ATG AC 
target_158-2 GGC CAA TTT GTA GAT GGA GTT TCC GGC GGT ATG AC 
 
 
Table 3.5.2 : APE assembly oligomers for ZF combinatorics  
Oligomer Name Sequence (5’ to 3’) 
Zif268_Oligo1fin3 ttgcgacatctgcggtcgtaaattcgctcgttctgacgaacgtaaacgtcacaccaaaatccacctgcgtcaga 
Zif268_Oligo3fin2 CCAatgtagaatttgtatgagaaatttctctcgttctgaccacctgaccacccacatccgtacccacaccggtgaaa 
Zif268_Oligo5fin1 tgaatcttgcgaccgtcgtttctctcgttctgacgaactgacccgtcatattagaattcatactggacaaa 
37-12Oligo1fin3 ttgcgacatctgcggtcgtaaattcgctCGTCACGACCAGCTGACCCGTcacaccaaaatccacctgcgtcaga 
37-12Oligo3fin2 CCAatgtagaatttgtatgagaaatttctctGACCGTGCTAACCTGCGTCGTcacatccgtacccacaccggtgaaa 
37-12Oligo5fin1 tgaatcttgcgaccgtcgtttctctCGTAACTTCATCCTGCAGCGTcatattagaattcatactggacaaa 
92-1Oligo1fin3 ttgcgacatctgcggtcgtaaattcgctGAACGTGGTAACCTGACCCGTcacaccaaaatccacctgcgtcaga 
92-1Oligo3fin2 CCAatgtagaatttgtatgagaaatttctctCAGCGTTCTTCTCTGGTTCGTcacatccgtacccacaccggtgaaa 
92-1Oligo5fin1 tgaatcttgcgaccgtcgtttctctGACTCTCCGACCCTGCGTCGTcatattagaattcatactggacaaa 
158-2Oligo1fin3 ttgcgacatctgcggtcgtaaattcgctCAGTCTACCTCTCTGCAGCGTcacaccaaaatccacctgcgtcaga 
158-2Oligo3fin2 CCAatgtagaatttgtatgagaaatttctctGTTCGTCACAACCTGACCCGTcacatccgtacccacaccggtgaaa 
158-2Oligo5fin1 tgaatcttgcgaccgtcgtttctctGACAAAACCAAACTGCGTGTTcatattagaattcatactggacaaa 
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Chapter 4: C2H2 ZF DNA Specificity Engineering 
 
4.1 Introduction 
 
 The ability to recombine ZF domains with distinct DNA specificities into linked ZFAs 
that target longer, unique sequences is a powerful tool for biotechnology and synthetic 
biology.  Following the successful generation and characterization of the 64 ZFA variants 
in Chapter 3, we next applied APE-MITOMI to engineering ZF specificity. We chose two 
different target sites, and starting from a ZFA with a different consensus target, 
sequentially introduced finger variants at different positions and evaluated their binding 
affinity towards a panel of closely related targets.  
 
 
4.2 Results 
 
4.2.1 ZFA Specificity Engineering for ‘GTA GAT GGC’ 
 
 We first decided to engineer a ZFA with a consensus sequence of ‘GTA GAT GGC’, 
taking advantage of the relatively well-populated selection of GNN-binding recognition 
helices (RHs) in the Zinc Finger Consortium database (ZF DB).  Starting with the WT 
Zif268 protein, we first modified F2 of Zif268 by replacing it with 16 RHs listed as ‘GAT’ 
binders (Figure 4.2.1). Characterizing these variants showed that there was considerable 
variability in the specificity and binding affinity of the 16 RHs tested.  Due to observations 
that the aspartic acid residue at position 2 of each α-helix of Zif268 is important for 
determining sequence specificity (139), causing specificity constraints, the same set of 16 
RHs were also used in a different F1/F3 context (37-12 framework, Figure 4.2.1).  
Additionally, by combining residues from RHs with high affinity and specificity towards 
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‘GAT’, a set of designed variants not found in the ZF DB were made, and these variants 
were placed into still another F1/F3 context (158-2 framework, Figure 4.2.1).   
 
Figure 4.2.1 : Heat map of DNA target affinity data from all ZFAs containing F2 variants that were selected to 
bind the triplet GAT in different contexts (different F1/F3 combinations).  The topmost 18 RH’s placed in the 
zif268 F1/F3 context exhibited the highest affinities for the GAT target, whereas the same set placed within 
the 37-12 F1/F3 context exhibited weakened affinities with no clear affinity for GAT.  As a final screen, the 
highest affinity variants from the zif268 screen were placed into the 158-2 F1/F3 context, in addition to seven 
‘designed’ RHs based on residue combinations from the highest affinity/lowest non-specific variants (F2B, 
F2E and F3D).  As observed in the zif268 context, the RH F2B (LLHNLTR) had the highest affinity, and was 
used as the F2 variant in subsequent screens for the other finger positions. 
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 One RH variant, LLHNLTR, consistently exhibited the highest affinity and decent 
specificity for ‘GAT’ in different F1/F3 frameworks.  This RH also displayed low levels of 
affinity towards other ‘GAN’ triplets, but considering its elevated affinity for our desired 
target, we deemed its specificity satisfactory.  We thus used this helix for the next selection 
step, which involved substituting RH variants into the F1 position to target ‘GGC’.  Initially, 
we tested the F1 variants using F3 from Zif268, and the new F2 variant from the ‘GAT’ 
selection round.  These protein variants exhibited high levels of degeneracy to the extent 
that it was not clear which, if any, of the F1 RH variants were specific to ‘GGC’ (Figure 
4.2.2).  In an effort to improve the target specificity, we performed a second screen using 
the same set of F1 variants for ‘GGC’, but with F3 from ZFA 158-2, along with the selected 
F2 variant from the ‘GAT’ selection (Figure 4.2.3).    
 The variants in Figure 4.2.3 displayed a similar specificity profile to those observed 
in Figure 4.2.2, but with reduced the non-specific background.  Nearly all of the RH 
variants, which were annotated in the ZF DB as binding ‘GGC’, appeared to have higher 
affinity for the closely related target ‘GTC’.  To advance the engineering process, we 
selected ESSKLKR as the best ‘GGC’ binder in position F1, considering its level of 
specificity for ‘GGC’ relative to ‘GTC’. We then performed a third and final screen by 
substituting RH variants which were reported to bind ‘GTA’ into F3 position (Figure 4.2.4).  
The RH that displayed the highest ‘GTA’ binding affinity and specificity, QSSALTR, did not 
exist in the ZF DB.  It was generated by selecting the highest frequency residue in each 
position from all of the ‘GTA’ RH variants listed in the database.   
 In order to characterize the actual specificity of our synthetic ZFA (F1 ESSKLKR, F2 
LLHNLTR, F3 QSSALTR), a 1-off target library was prepared for the consensus 
sequences: ‘GTA GAT GGC’ and ‘GTA GAT GTC’ (Figure 4.2.5). Given the relatively poor 
performance observed during the F1 (‘GGC’ variants) selection step, the engineered ZFA 
exhibited a surprisingly high affinity and specificity for the intended target consensus 
sequence (‘GTA GAT GGC’). In an attempt to improve the specificity of our engineered 
variant for the intended target, we performed an additional screen using 14 designed RH 
variants which were anticipated to bind ‘GGC’ based on online DNA binding site predictors 
(75, 76, 145, 276) (Figure 4.5.1), but nearly all these variants displayed a higher affinity for 
GTC and thus failed to further improve the specificity of the engineered ZFA (Figure 4.2.5). 
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Figure 4.2.2 : Heat map of affinity data from F1 RH variants selected to bind GGC with F3 from zif268 and 
F2-LLHNLTR from the GAT selection screen.  Due to nonspecific binding for nearly all GNN targets, there is 
no clear RH with high specificity for GGC, and so a second screen was performed with a different F3 (Figure 
4.2.3). 
 
 
 
 
Figure 4.2.3 : Heat map of affinity data from F1 RH variants selected to bind GGC with F3 from 158-2, which 
resulted in a weakened affinity across the entire target range, but also reduced the non-specific binding 
‘noise’ seen in Figure 4.2.2.  In this screen, while there is no high-specificity variant for GGC, by comparing 
the relative specificities for GGC and GTC, F2B ESSKLKR was selected.  The ‘logo’ RH at the bottom of the 
heat map was generated by taking the highest frequency residue in each RH position from all available GGC 
variants listed in the Zinc Finger Database. 
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Figure 4.2.4 : Heat map of affinity data from F3 RH variants selected to bind GTA, with the selected RHs 
from the F2 and F1 screening rounds.  In this screen, the highest affinity variant was the ‘logo’ design, which 
was generated by taking all of the available GTA variants listed in the Zinc Finger Database and selecting 
the highest frequency residue at each position (QSSALTR).  This RH was chosen to complete the 3 selection 
rounds towards developing a ZFA that recognizes the sequence GTA GAT GGC. 
 
 
 
Figure 4.2.5 : Heat map of affinity data from the final engineered variant (top row) selected to bind GTA GAT 
GGC, in addition to 14 other F1 variants which were predicted (Figure 2.5.1) to bind more specifically to GGC 
than those tested in the earlier F1 selection round (Figure 4.2.3).  Here all of the variants are tested against a 
1-off target library to generate a detailed summary of specificity towards the target of interest.  Despite the 
DNA specificity predictions given for the designed F1 variants, most of them also have a preference for GTC 
rather than the desired target GGC. 
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4.2.2 ZFA Specificity Engineering for ‘GCC CAC GTG’ 
 
We repeated the same sequential selection process to engineer another ZFA 
recognizing the sequence ‘GCC CAC GTG’, which is a more challenging target sequence 
given the ‘CAC’ in the F2 position.  The most populated ZF designs in the ZF DB exists for 
fingers targeting ‘GNN’ motifs.  The selection of designs for ‘CNN’ binding variants is 
considerably reduced, and to generate enough designs that bind ‘CAC’, we selected RHs 
from recent publications (see caption for Figure 4.2.6) but also conceived of new designs 
based on structures from those publications.   
 
 
Figure 4.2.6 : Complete heat map data from all ZF TFs containing F2 variants that were selected or designed 
to bind the triplet CAC with F1/ F3 from Zif268.  Due to a low list of options from the Zinc Finger Consortium 
Database, RHs were taken from recent publications, which reported CAC-binding ZF domains.  CAC1, 5 and 
6 came from (140), CAC2 and 3 came from (75), and CAC21 was taken from a patent application (2004, 
EP1421177A2).  The remaining RHs were designed around the amino acid residue logos presented for CAC 
(75) or from half-site designs reported in (152).  In this initial screen, using F1/F3 from zif268, it appeared 
that none of the RHs were functional for binding CAC, and instead we observed strong affinity for GAN or 
TAN targets.  
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As with the specificity engineering process in 4.2.1, we started with the Zif268 
F1/F3 domains, and inserted a set of 23 F2 variants that bind ‘CAC’ (Figure 4.2.6).  This 
first screen hinted at a few RH variants that may bind ‘CAC’, but the majority of the 
designs displayed high specificity and affinity towards ‘GAN’ and ‘TAN’ targets.  We 
believe this result can be explained by the strong cross-site interaction of the Zif268 F3 
aspartic acid in position 2 of the RH, which had been previously observed (139).  The 
natural F2 target in Zif268 is TGG/GGG, and so the cross-strand interaction would prefer 
an A or C in the first base of the F2 target complement, which was only available in the 
GNN and TNN targets.  Since the F2 variants were selected for binding ‘CAC’, the second 
base that is recognized is an ‘A’.  Because this screen with F1/F3 from Zif268 did not 
produce any high affinity CAC binding variants, we performed a second screen (Figure 
4.2.7) using F1/F3 from a recent publication testing ‘CNN’ binding variants (75). 
 
 
Figure 4.2.7 : Heat map of affinity data from all ZFAs containing F2 variants that were selected or designed 
to bind the triplet CAC with F1/ F3 from (75).  This F1/F3 set is the context within which CAC2 and 3 were 
originally tested, so we knew at least these variants should be specific for CAC.  As reported in ref 22, CAC1 
displayed only weak binding towards CAC.  While most of the variant designs did not come from published 
examples, many of them were capable of binding CAC, but with reduced specificity.  In the end, variant 
CAC13 was chosen for subsequent screens since it was a novel design and exhibited relatively high 
specificity and affinity towards CAC.   
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Some of the ‘CAC’ designs we tested within F1/F3 from Zif268 were originally 
developed and tested within the F1/F3 context (referred to as the ‘Persikov’ framework for 
the first author) from this publication.  Since these designs had been previously validated 
in another study, we were confident they would function as a good control for screening 
new ‘CAC’ variants.  As expected, within the proper F1/F3 context, many of the designs in 
our screen showed high affinity and specificity for the desired ‘CAC’ target.  We chose the 
F2 variant ESGNLRS since it displayed high affinity and specificity towards CAC and was 
an entirely novel ZF design.  The next step involved substituting variants into the F1 
position that were expected to bind ‘GTG’, and here, the F1 variant was very easy to select 
since the majority of the designs from the ZF DB did not display high affinity towards the 
target panel (Figure 4.2.8).  The RH variant RKDVLTR was chosen since it displayed 
exceptional binding affinity and specificity to the ‘GTG’ target. 
 
 
Figure 4.2.8 : Heat map of affinity data from F1 RH variants selected to bind GTG with F3 from (75) and F2 
(ESGNLRS) from the CAC selection in Figure 4.2.7.  A large majority of the RHs tested were not functional, 
or bound with relatively low affinity, and many of the variants had a binding preference for GTC in addition to 
the desired target GTG. RH variant RKDVLTR was selected for the subsequent screens in spite of its 
secondary binding preference for GTC. 
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The third and final selection round involved inserting RH variants for F3 that were 
expected to bind the target ‘GCC’.  Finding a high affinity, yet specific RH in position F3 for 
GCC was more challenging and we settled on using a RH that displayed high affinity 
towards both ‘GCC’ and ‘GTC’ (Figure 4.2.9).  The RH variant EGGTLRR was selected for 
use in the final engineered ZFA design.   
 
 
Figure 4.2.9 : Heat map of affinity data from F3 RH variants selected to bind GCC with F1 from the GTG 
selection in Figure 4.2.8 and F2 from the CAC selection in Figure 4.2.7.  In this selection, the majority of the 
variants were functional and displayed high specificity for GCC, but the highest affinity variants also 
displayed non-specific binding to other triplets.  A selection of these variants was also characterized against 
a 1-off target library (Figure 4.2.10). 
 
Although each individual RH appeared to bind the intended target sequence with high 
specificity, when testing the engineered ZFA against a one-off library, the highest affinity 
target was ‘GTC CAT GTG’, not the desired target ‘GCC CAC GTG’, which was bound with 
a lower affinity (Figure 4.2.10). Other RHs from the F3 ‘GCC’ screen (Figure 4.2.9), which 
displayed lower affinity but higher specificity for ‘GCC’ were also tested against a one-off 
library, but all of these exhibited higher affinity for other targets than ‘GCC CAC GTG’.  
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Figure 4.2.10 : Heat map of affinity data from the final engineered ZFA selected to bind GCC CAC GTG, in 
addition to several other F3 (GCC) variants, which displayed lower affinity but higher specificity to GCC.  
Here all of the variants are measured against a 1-off target library based on the consensus sequences ‘GCC 
CAC GTG’ and ‘GTC CAC GTG’ to generate a detailed evaluation of their specificity towards the target of 
interest.  All of the variants have some affinity for CAT rather than CAC, and it becomes clear that a few of 
the F3 variants have a preference for GTC rather than GCC.  In most cases, the target of interest (GCC CAC 
GTG) is bound, but with equivalent or lower affinity than other targets. 
 
These results indicate that engineering ZFAs to bind a particular sequence is 
relatively easy to achieve using a stepwise selection process, but engineering the precise 
specificity landscape is more challenging.  The individual specificity profiles of RHs can 
vary considerably, and in some instances do not reflect their annotated or predicted 
sequence specificity given in the ZF Consortium Database or online binding site 
predictors.  One significant advantage of APE-MITOMI based assembly and 
characterization is the fact that the method returns information on the precise specificity 
landscape and affinity of the synthesized transcription factors during all stages of 
assembly.  APE-MITOMI allows the generation of ZFAs with similar consensus 
sequences, but different specificity and/or affinity profiles and enables the examination of 
these characteristics for the function of native and synthetic transcriptional regulatory 
networks. 
 
 
4.3 Discussion 
  
As demonstrated in the two engineering studies detailed in this chapter, by using 
previously published RHs from a variety of sources, in addition to binding site predictor 
softwares, the rational design of ZFAs is possible.  The use of the APE-MITOMI enables 
the rapid production of linear template libraries of ZFA gene variants and high-throughput, 
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quantitative mapping of their binding specificities.  Although the Zinc Finger Consortium 
Database was a useful resource for selecting ZF domain parts, future experiments should 
incorporate a computational screening step prior to selecting variants for APE assembly.  
This would improve the rate of selecting functional designs and help to limit the number of 
variants that need to be screened before finding designs that meet the engineering 
objectives.   
Although both of our engineered variants exhibited off-target binding, these designs 
were only the first implementation of our rapid protein engineering platform.  We did not 
explore the possibilities of making larger ZFAs that contain more than 3 linked ZF 
domains.  Longer ZFAs bind to longer target sites, so that degeneracy in a single finger 
position may be overcome by including additional domains with high specificity.  In addition 
to improving the specificity of an engineered ZFA with additional ZF domains, the affinity 
can also be augmented (277).  Another potential option to explore for improving the 
specificity of engineered variants would be to perform the rounds of selection in a different 
order.  Beerli and Barbas recommend three different strategies for producing ZFAs with 
engineered binding specificity: parallel, sequential and bipartite selection (154).    
As studies related to ZF domains are continuously being performed, new results are 
offering added insight into how amino acid sequence, linker structure, and neighboring ZF 
domains influence target specificity (278, 279).  Data from these studies are leading to 
improved models of ZF-DNA interactions and aiding motif prediction algorithms, which in 
turn will help make a technique like APE-MITOMI more powerful for generating and testing 
rationally designed variants. 
 
 
4.4 Methods 
 
The methods used in this Chapter are identical to those detailed in Chapter 2 (for APE 
assembly and linear template preparation) and 3 (for ZFA assembly, MITOMI 
characterization, and data analysis). 
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4.5 Supplementary Figures  
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Figure 4.5.1 : Two tables of predicted DNA binding specificities for GGC-binding variants taken from the ZF 
Consortium Database, and novel variants created by substituting in new residues, using online prediction 
programs (75, 76, 145, 276).  The amino acid sequence of the complete ZFA sequence (containing all three 
ZF domains) is given as input to the programs, which detect the RHs (residues -1 to 6) then predict the DNA 
binding site of each ZF domain.  In the figure above, the leftmost column provides the amino acid sequence 
of the RH variant of interest.  The output of each program is given in either the second or third column, 
respectively, as sequence logos.  The fourth column indicates whether the two predictions agree with each 
other, and the final column compares the prediction with the observed MITOMI binding preference (target 
bound with the highest affinity). 
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Chapter 5: C2H2 ZF Affinity Variant Engineering 
 
5.1 Introduction 
 
Focus in ZF engineering has been on rationally designing ZF specificity, but it is 
unclear to what extent affinity can be tuned and whether affinity can be tuned 
independently of sequence specificity.  The ability to tune ZF affinity is of interest in 
creating synthetic transcriptional regulatory networks (156) and it would drastically simplify 
the task of engineering ZFAs if affinity could be tuned independently of specificity.  Based 
on the Zif268 crystal structure we selected 28 residues that could be involved in 
determining the protein’s affinity to DNA, and changed these residues to alanine (Figure 
5.1.1).  These variants were assembled and characterized using APE-MITOMI to evaluate 
how these modifications altered binding specificity and affinity.  Each experiment was 
performed with WT Zif268 present in each MITOMI device, and all variants were tested 
against a dilution set of the Zif268 consensus target, as well as single concentrations of a 
1-off target library based on the Zif268 consensus sequence (‘GCG TGG GCG’).  Changes 
in binding affinity towards the consensus target were determined using data from the 
consensus target dilution set.  Changes in binding specificity were determined using data 
from the 1-off target library.   
 
? 94 
 
Figure 5.1.1 : Alignment of amino acid residues from the ZF domains of Zif268, where magenta circles 
indicate positions that make non-specific contacts with the DNA target backbone, based on the crystal 
structure of Zif268 with its consensus target.  These positions were mutated to alanine to evaluate their effect 
on DNA binding affinity. Underlined residues indicate the location of the recognition helix (-1 to 6) of each ZF 
domain. 
 
5.2 Results 
 
In all previous analyses of ZFA binding, a ‘relative affinity’ value in arbitrary 
fluorescence units was calculated from observed levels of bound target, total target, and 
total protein to generate a single value (see Equation 3.4.1).  For analyzing the affinity 
variants, the fold change in binding affinity towards the WT Zif268 consensus target was 
determined using the target dilution series data set for each variant.  By taking the ratio of 
surface bound target DNA to surface bound protein (Cy5bound/GFP) and plotting the ratio as 
a function of total target DNA (Cy5total, also in AFU), a linear fit was used to derive a slope 
value which was taken as the ‘relative affinity’ for the consensus target (Figure 5.2.1).  
 
 
 
 
 
 
 
 
 
Figure 5.2.1 : Example of plotting MITOMI data from a target dilution series to derive a ‘relative affinity’. 
 
Relative affinity values were calculated in this manner for each variant.  Fold change in 
binding affinity was determined by dividing the average relative affinity for each ZFA 
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variant by the average relative affinity for Zif268.  As expected, most alanine substitutions 
resulted in modest decreases in affinity as compared to wildtype (WT) Zif268 (up to 2-fold; 
Figure 5.2.2).  To our surprise, a few modifications led to increased binding affinity (R14A, 
I28A, R70A).  In addition to testing the alanine substitution variants, residues from Sp1 (a 
TF with a 3-finger ZFA domain, commonly used as an alternative to the Zif268 framework 
(117, 280)), were placed into the few positions which exhibited increased binding affinity in 
the alanine scan.  Four of these non-alanine residue changes also led to increases in 
binding affinity, and may partially explain differences in binding affinity observed between 
artificial TFs designed using the Zif268 and Sp1 frameworks. 
 
        
Figure 5.2.2 : (Left) Results of single residue alanine scan at the residue positions listed and the resulting 
fold-change in binding affinity relative the WT zif268 consensus target. (Right) Results of single residue 
substitutions using non-alanine amino acids, taken from the Sp1 framework. 
 
 
Figure 5.2.3 : Rank ordered fold-change in binding affinity relative to WT consensus target for single and 
multiple mutant variants. 
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Given that the single substitutions primarily resulted in modest affinity decreases, we 
proceeded to assemble and test 22 double substitutions, 6 triple substitutions and 1 
quadruple substitution (Figure 5.2.3).  These novel mutants allowed us to extend the 
dynamic range to 1/5 of WT and allowed us to smoothly tune affinity over the entire 
accessible range between 2x increased and 5x reduced affinity. 
We could also show that most of the alanine substitution mutants retain their 
specificity landscape, indicating that affinity can be tuned independently of specificity.  The 
Spearman’s rank correlation coefficient was determined by comparing the relative affinity 
values of each variant with those of Zif268, when tested with a 1-off library based on the 
Zif268 consensus target (Figure 5.2.4).  Except for two alanine mutants (F16A and H25A), 
most of the other affinity variants exhibit nearly identical binding specificity compare to WT 
Zif268, but display at wide range of affinities.  
 
 
Figure 5.2.4 : Analysis of data obtained from examining Zif268 alanine substitution affinity variants (Figure 
5.2.2) tested against a 1-off target library for the Zif268 consensus target (GCG TGG GCG).  Spearman’s 
rank correlation coefficient was determined by comparing relative affinity values with Zif268 for the 1-off 
target library.  Nearly all of the variants correlate highly, meaning none have lost their target specificity in 
spite of their affinity being modulated (fold change in affinity values derived from experiments using a dilution 
series of the Zif268 consensus target).   
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The majority of variants have a Spearman’s rank correlation greater than 0.9, except for 2 
variants, F16A and H25A, which displayed severe departures from the specificity of the 
WT protein as a result of the mutation.  These variants have a higher than expected affinity 
for certain targets, and lower than expected affinity for others as seen in the individual 
scatter plots displayed in Figure 5.5.1.   
 
 
5.3 Discussion 
 
  In this chapter, we demonstrate the utility of APE-MITOMI to rapidly construct ZFA 
variants for modifying target binding affinity.  This work was initially inspired by results 
given in a recent publication detailing the development of synthetic TFs (sTF) for 
eukaryotic gene networks(156).  It is interesting to note that in this publication, they report 
the creation of sTFs with tunable transcriptional output by replacing multiple arginines with 
alanines in the ZF-backbone, but to see a decrease in output, they needed to make three 
or more mutations.  These in vivo results correspond well with what was observed in vitro 
using our affinity variants, since many of the single and double R?A mutations lead to an 
increased binding affinity.  The ability to tune affinity independently from specificity is an 
incredibly useful tool for improving weak, but highly specific interactions.  Since these 
modifications are made to the framework sequence of ZFAs, it should be applicable to any 
of the protein designs that have been made in Chapter 3 or 4.  Another option for tuning 
affinity, which was not explored in this thesis, would be to explore how the linking 
sequence between ZF domains affects DNA binding specificity or affinity.  Previous 
studies reported the development of extremely high affinities simply by changing the linker 
design (154, 277, 281) . 
 
 
5.4 Methods 
 
The methods used in this Chapter are identical to those detailed in Chapter 2 (for 
APE assembly and linear template preparation) and 3 (for ZFA assembly, MITOMI 
characterization, and data analysis). 
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5.5 Supplementary Figures 
Figure 5.5.1 : For each variant, we fit a curve to the 1-off target data set, using a linear (blue), exponential 
(yellow) or log (red) equation to capture the behavior of the data.  The black dashed line signifies the 
behavior of WT Zif268 plotted against itself, to compare against the behavior of the mutant variants.  
Variants with increased binding affinity towards 1-off targets have curve fits above the dashed black line.  
Those with decreased binding affinity have curve fits below the dashed black line.  The curve fit constants 
and R2 value is reported beside each plot. 
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Chapter 6: Conclusions and Outlook 
 
The work presented in this thesis outlines the development of a novel approach towards 
accelerating protein engineering.  By coupling a gene assembly strategy with high-
throughput on-chip protein expression, purification, and quantitative characterization, we 
demonstrate that it is possible to completely circumvent molecular cloning and cell-based 
processing steps generally needed in protein biochemical analysis.  Integration of these 
methods reduced the time required between protein design and protein characterization 
from weeks to days.  We validated the utility and versatility of this process by synthesizing 
over 400 zinc finger array (ZFA) variants, and characterized the binding specificity of each 
for a total of over 98,000 protein-DNA interaction measurements.  
 
In Chapter 2, we described the process for developing a solid-phase, ligase and restriction 
enzyme-free gene assembly technique that utilizes commodity-scale DNA oligomers 
without the need for purification steps.  The error rate of this technique was found to be 
competitive with other methods, and the modularity of the assembly process allows for the 
construction of both diverse and repetitive gene elements.  Since the assembly technique 
utilizes magnetic beads, it is amenable to scale-up via robotic liquid handling systems. 
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In Chapter 3, we explored the modularity of ZFAs, and using a limited set of DNA 
oligomers, assembled a library of protein variants and mapped their binding specificity 
profiles using MITOMI.  The results of this study validated the speed and sensitivity of 
APE-MITOMI, and proved that our platform could be extended towards other ZFA 
engineering applications.  
 
In Chapters 4 and 5, we applied the APE-MITOMI process towards rationally designing 
specificity and affinity ZFA variants.  We took advantage of existing ZF protein structure 
databases and models to engineer two ZFA variants that bind specific target sequences.  
The binding specificity landscapes for both variants were mapped throughout each cycle of 
design, assembly and characterization, providing a detailed overview of the engineering 
process.  Additionally, by selectively introducing alanine substitutions into the ZFA 
framework outside of regions that control specificity, we were able to create ZFA variants 
for tuning binding affinity without affecting specificity. 
 
The application of APE-MITOMI towards the engineering of C2H2 ZF variants was only a 
proof-of-concept for rapid prototyping of synthetic biological designs.  In general, the APE 
gene assembly technique could be used for potentially any kind of protein engineering 
application, particularly for instances where protein variants are very similar in sequence, 
and where crystal structures are readily available to guide the selection of novel designs.  
Some instances of projects that could already be initiated include examining the protein or 
RNA-binding activity of ZFAs, or engineering other types of protein domains.  Repeat or 
solenoid proteins would be interesting to explore, since they are modular, well 
characterized, can mediate a range of protein-protein interactions, and have been applied 
to engineering applications (282).  Still other protein structures that could be studied are 
scFvs and nanobodies (283), designed ankyrin repeat proteins (DARPins) (284), PDZ 
domains, leucine zipper domains, SH2/SH3 domains, and also engineering new functions 
from existing protein structures (130).  One interesting option outside of protein 
applications would be to study oligonucleotide aptamers (70). 
 
It has been shown previously that over 400 full-length drosophila transcription factors of 
varying size and families could be expressed on a single MITOMI device (210), indicating 
that there is no major bottleneck to on-chip protein expression. Although all of the genes 
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studied in this thesis were prepared on bench-top by hand, the APE gene synthesis 
method can be readily automated on liquid handling robots, eliminating the last limitation in 
the process.  It should thus be possible to characterize thousands of synthetic protein 
variants per week, which in turn will enable exploration of the protein sequence-function 
relationship in unprecedented detail, aid in the development of accurate computational 
predictions of protein function, and allow us to rapidly engineer novel proteins. 
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